🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email me.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

🛒 Check out our newly launched MERCH STORE.

Subscribe now

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

The FDA approved three first-in-class drugs this week. Moderna’s mFluSiva is the first licensed influenza vaccine built on mRNA. Takeda’s Orzeyful (oveporexton) is the first orexin receptor 2 agonist, and the first drug that treats narcolepsy type 1 by restoring the signal patients have lost rather than just stimulating them around it. Both open new categories, not just single product approvals. And in Moderna’s case, the FDA had issued a refusal to file on this exact program only 18 months ago.

The FDA also granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) on August 6, four days after the August 2 decision deadline and one week after its advisory committee voted 10-3 that the efficacy data are evaluable and clinically meaningful. This is Replimune’s third review cycle after rejections in July 2025 and April 2026.

The second story is obesity, and the race isn’t close anymore. Lilly booked $23B in the quarter, up 48% and raised full year guidance to $85B to $87B, driven by tirzepatide alone. Novo missed on the oral Wegovy line and, more damaging, disclosed that CagriSema failed to prove non-inferiority to tirzepatide on blood sugar in the head-to-head REIMAGINE 4 trial. That’s the second direct loss to Lilly’s molecule in six months, after CagriSema missed on weight in REDEFINE 4. Novo’s CEO spent the earnings call talking about small acquisitions to fill pipeline gaps, which usually means the company can’t fix things with its own pipeline.

Capital markets had a busy week too. Five biotechs went public and raised more than $1 billion combined, bringing 2026 to 17 IPOs and 12 that raised at least $250 million each. All of 2025 only produced 11. Meanwhile, the Financial Times mentioned a rumored $400 billion merger between AstraZeneca and Bristol Myers Squibb, which knocked about 9% off AstraZeneca’s stock before the whole story was denied by an insider. So investors are happy to pay premium prices for fresh science and clearly don’t want to pay for consolidation between two aging pipelines.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 The FDA approved Moderna’s mFluSiva on August 5 for seasonal influenza in adults 50 and older. Standard approval in the 50 to 64 group, accelerated approval in 65 and older contingent on a confirmatory trial running across two flu seasons. The pivotal data showed a 27% relative reduction in influenza-like illness compared with a standard dose flu shot in adults 50 and over, with no new safety signals. What matters here almost as much as the approval itself is the regulatory part of it. Moderna received a refuse-to-file decision on this exact program under Marty Makary and Vinay Prasad. Both are gone from the agency, a June advisory committee voted unanimously in favor, and the product is now approved in time for the 2026-2027 season. The commercial case rests on manufacturing speed. Conventional flu vaccines require a strain call months ahead of the season and a production run that can’t be revised, but an mRNA process can. If the confirmatory data hold in the 65+ population, strain match becomes the whole commercial argument against Sanofi, GSK, and CSL.

🔹 Takeda’s Orzeyful (oveporexton) was approved August 5 for narcolepsy type 1 in adults, the first medicine to target the biology of the disease directly. Narcolepsy type 1 is caused by loss of orexin-producing neurons, and existing therapy is stimulants and sodium oxybate, which manage symptoms without touching the deficit. Jefferies puts the annual price between $142k and $250k, and roughly $2B in peak sales at the low end. Launch waits on the Drug Enforcement Administration, which has up to 90 days to assign a control schedule. The phase 3 FirstLight and RadiantLight data behind the approval were clean. Mean sleep latency on the Maintenance of Wakefulness Test improved by 13.83 minutes at 1 mg and 17.2 mins at 2 mg against placebo, both at p<0.001. Weekly cataplexy rate fell more than 80% from baseline relative to placebo, with patients reporting four to five cataplexy free days a week at week 12 against none at entry. The interesting question is where the class goes, not the specific drug. Alkermes is running alixorexton across narcolepsy type 1, type 2, and idiopathic hypersomnia, explicitly to arrive with a broader label than Takeda’s. Lilly bought into the mechanism through the $6.3B Centessa acquisition. Eisai has its own candidate. Takeda gets first mover pricing in the smallest of the three indications, and the larger populations are still open and that’s where the class gets decided.

🔹 The FDA granted accelerated approval to Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) on August 6 for advanced melanoma in patients who have progressed on anti-PD-1 therapy, in combination with nivolumab. Tudriqev is a genetically modified oncolytic viral therapy based on herpes simplex virus type 1, injected directly into tumors every two weeks for eight doses. In the pivotal single arm trial of 91 evaluated patients, 24% achieved an objective response with a median duration of 14.1 months. The approval landed four days after the August 2 decision deadline and one week after the Cellular, Tissue and Gene Therapies Advisory Committee voted 10-3 that the efficacy data are evaluable and clinically meaningful. This is Replimune's third review cycle. The FDA had previously rejected the application in July 2025 and April 2026, and briefing documents released two weeks before the panel meeting had called the trial "not interpretable" on the grounds that a single arm intratumoral injection study couldn't separate RP1's contribution from Opdivo's. The panel disagreed and the FDA, eventually, agreed with the panel. Two weeks produced a briefing document that took 30-40 % off the stock, a panel vote that doubled it, a deadline that passed, and finally an approval four days late.

🔹 Lilly reported $23.0B in Q2 revenue, up 48%, against a $20.6B consensus. Mounjaro rose 91% to $9.94B worldwide, US Zepbound rose 44% to $4.9B, non-GAAP earnings per share rose 33% to $8.38, and full year guidance moved to $85.0B to $87.0B from $82.0B to $85.0B. Foundayo, the oral GLP-1, brought home $98M in its first reported quarter against $104M expected, which nobody punished because expectations were already low. Novo’s oral Wegovy came in at DKK 3.2B, about $494M, versus DKK 3.6B expected, and the shares fell 6%. Novo did raise its own full year sales forecast, from a range of down 4% to down 12% to a narrower range of flat to down 6%. But the direction of the franchise isn’t really in question. Lilly is growing at 48% on an injectable that has now beaten Novo’s next generation combination twice head to head.

🔹 Novo Nordisk’s CagriSema was compared head-to-head against Lilly’s tirzepatide 15 mg in about 1,000 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor, over 68 weeks. On weight, CagriSema was non-inferior at 15.2% versus 15.8%. On glycemic control, it wasn’t. HbA1c fell 1.9 percentage points versus 2.2 for tirzepatide, missing the non-inferiority margin. A 1.9-point HbA1c reduction is a strong result in absolute terms and would have been a big headline against placebo three years ago. But Novo chose the comparator, chose the dose, and lost on the primary endpoint. Combined with REDEFINE 4, where CagriSema missed non-inferiority on weight in obesity, the amylin+semaglutide combination has now been tested directly against Lilly’s molecule twice and come up short on both axes that matter commercially. So CagriSema’s launch case has to be built on tolerability or price rather than efficacy.

🔹 The Financial Times reported on August 3 that AstraZeneca and Bristol Myers Squibb had held early talks about combining, which would have created a roughly $400B company and one of the largest deals in the industry’s history. AstraZeneca’s shares fell as much as 7-9%. On Aug. 5, a senior source told Reuters there never was a deal and there are no discussions. The London listing recovered about 3%. Whether talks actually happened is unresolvable from the outside. The shareholder reaction, however, is not ambiguous. AstraZeneca has a functioning oncology and cardiometabolic pipeline, and the mere suggestion that it would spend its equity on Bristol Myers, whose Revlimid and Eliquis patent cliffs are the reason it would want the deal, cost it nearly a tenth of its market value in a day.

🔹 Braveheart Bio raised $382.5M, pricing 21.25M shares at $18 for BHB-1893, a cardiac myosin inhibitor licensed from Hengrui Pharma for hypertrophic cardiomyopathy and aimed at Bristol Myers’ Camzyos. Hengrui is running Phase 3 in the obstructive form in China. Braveheart plans global trials in both obstructive and non-obstructive disease starting late 2026. Attovia raised $289M at $17 for a $767M valuation on ATTO-1310, an antibody against interleukin-31, the itch cytokine, in Phase 1 for chronic pruritus and severe eczema. Braveheart is the 17th drugmaker to go public in 2026 and Attovia the 12th to raise at least $250M, against 11 offerings in all of 2025. Median deal size this year is around $300M. Braveheart is also the second listing of 2026 built on a Hengrui-licensed molecule, which means the China licensing arbitrage model has now moved from private deal rooms into the public markets.

🔹 Tarsus Pharmaceuticals is acquiring Alkeus for about $450M upfront, $270M cash and $180M stock, plus up to $350M in milestones and a low to mid single digit revenue share. The asset is gildeuretinol (ALK-001), a daily oral in Phase 3 for Stargardt disease, an inherited retinal degeneration with no approved treatment. The mechanism is deuteration of vitamin A to slow the dimerization that produces toxic retinal byproducts, and the drug has been studied in more than 400 individuals. Tarsus is spending the balance sheet from its marketed eye care product on a late stage rare disease program in an indication where any approval is the first.

🔹 Intellia disclosed that an analysis of more than 600 patient samples across the nex-z program identified a specific human leukocyte antigen allele associated with the largest liver transaminase elevations seen in the trials. The company will return HLA genotyping results to investigators and to patients already enrolled or entering screening in the phase 3 studies, and is discussing the finding with regulators. Enrollment, which had been paused after a grade 4 transaminase and bilirubin elevation in a patient who later died, has been restarted. MAGNITUDE-2 in hereditary ATTR with polyneuropathy should complete enrollment in the second half of 2026. This is arguably the most useful thing to happen to in vivo gene editing safety this year. The standing problem with the field is that a one time, irreversible edit leaves no way to de-risk an individual patient after the fact. An inherited immune genetic marker that flags who’s likely to mount the hepatic response converts an unpredictable platform risk into a screening step, if regulators accept it.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Front page image source: Stocktwits

A platform for personalized medicine

Genomic medicine off the shelf: LNPs as a platform for interchangeable, personalized molecules.

View analysis

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

🛒 Check out our newly launched MERCH STORE.

Subscribe now

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

Earnings week showed a clear contrast in how big pharma is spending. Sanofi wrote off about €1 billion (€952M of it on amlitelimab, an OX40 ligand antibody) and killed three immunology programs. GSK announced £1.9 billion in annual cuts and is closing its Stevenage research site. Takeda, Regeneron and Bristol Myers all trimmed programs in the same 48 hours. But at the same time, argenx paid $2.2 billion (an 86% premium) for Forte Biosciences and its first in class CD122 antibody, and Johnson & Johnson committed $785 million upfront on Sail Biomedicines, a preclinical in vivo CAR-T platform, with an option to buy the whole company for another $2.58 billion. Big pharma isn't abandoning immunology but it seems to be abandoning conventional antibody immunology. What they will pay up for right now is mechanism novelty with a clinical signal, or a delivery technology that changes the economics of an approved modality.

The other big thread was regulatory. The FDA’s advisory committees are back, and they’re not being gentle. A panel voted 9-3 that Capricor had not shown enough evidence that deramiocel works in Duchenne cardiomyopathy, with reviewers describing the cardiac benefit as a mirage produced by revising the statistical analysis plan. A day earlier, briefing documents called Replimune’s melanoma trial “not interpretable” and the stock lost 30 to 40% before the panel even met. Both companies are on their second or third try at the same approval. The convenient story since Marty Makary left has been that this FDA is looser. What’s actually happening is that contested cases are being sent to public panels rather than handled inside the agency, which puts the risk on shareholders and makes the briefing document itself the tradable event. The acting chair of the FDA’s oncology panel also resigned this week, leaving a thin bench thinner.

Last thing worth noting is that incretins keep finding new organs to work on. Altimmune’s pemvidutide cut heavy drinking days by 1.45 more per week than placebo in alcohol use disorder, every key secondary hit, and a biomarker of alcohol intake was down at p<0.0001. Small trial, about 100 patients over 24 weeks, but alcohol use disorder has three approved drugs that basically nobody takes, and this is the first controlled mid stage trial of a glucagon/GLP-1 dual agonist to read out in the indication. Still early but it keeps alive the idea that the metabolic platform reaches into addiction.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 argenx is acquiring Forte Biosciences for about $2.2B, $77 per share in cash via tender offer, roughly an 86% premium to Forte’s volume weighted average price since it reported positive phase 1b vitiligo data on July 9. The asset is FB102, a first-in-class antibody against CD122, the shared receptor subunit that gates interleukin-2 and interleukin-15 signalling in pathogenic T cells and natural killer cells. Forte has clinical proof of concept in two very different diseases, vitiligo and celiac, which is what argenx is paying the premium for. The company is pitching FB102 as a pipeline in a product, with alopecia areata and other autoimmune indications behind it. Strategically this is argenx buying a second engine. Vyvgart (efgartigimod) is a neonatal Fc receptor blocker that clears pathogenic antibodies, and it is carrying essentially the whole company. CD122 attacks upstream cellular drivers instead, and it’s a mechanism argenx doesn’t otherwise run. Three weeks from a Phase 1b readout to a signed $2.2B tender offer is the fastest data to deal conversion of the year.

🔹 Johnson & Johnson is paying $785M upfront, including a $465M equity investment, for an exclusive option to acquire Sail Biomedicines outright for $2.58B. Sail was formed from the 2023 merger of Flagship Pioneering’s Senda Biosciences and Laronde, and combines circular “endless RNA” payloads with programmable nanoparticles to reprogram T cells inside the patient rather than in a manufacturing suite. The lead program, SAIL-0839, is still preclinical and its target disease has not been disclosed. J&J is buying the manufacturing thesis, not a molecule. Conventional CAR-T requires apheresis, ex vivo engineering and lymphodepleting chemotherapy, which is tolerable in relapsed blood cancer and unworkable in lupus or myositis. In vivo delivery is the only route to autoimmune scale volumes. That logic is now consensus, which is why at least six in vivo CAR-T developers have been bought since early 2025, Eli Lilly taking Kelonia and Bristol Myers taking Orbital among them.

🔹 The FDA’s Cellular, Tissue and Gene Therapies committee voted 9-3 on July 29 that Capricor had not demonstrated substantial evidence of effectiveness for deramiocel in Duchenne-related cardiomyopathy. Agency reviewers argued the benefit was “essentially a mirage aided by switching up a statistical analysis plan” and that the changes “lack a scientific basis.” The arithmetic supports the charge. Under a revised statistical model, the left ventricular ejection fraction effect moved from 2.4 percentage points at p=0.04 to 1.8 points at p=0.09. Panelists called the findings fragile. The decision date is August 22, following a complete response letter in July 2025. Two days earlier the same dynamic hit Replimune, whose shares fell roughly 30 to 40 percent when reviewers called the single-arm IGNYTE trial for RP1 plus nivolumab “not interpretable,” on the grounds that an intratumoral injection study can’t separate a systemic anti-cancer effect from a local one. RP1 posted a 33.6% objective response rate and a 24.8 month median duration of response in anti-PD-1 failed melanoma, and has already been rejected twice, in July 2025 and April 2026. Its panel met July 30 on a single question, whether the results are evaluable and clinically meaningful, with a decision due August 2.

🔹 GSK is taking out about £1.9B ($2.5B) in annual costs over three years, closing its Stevenage research site and building a new global research centre in Cambridge, UK. The forcing function is dolutegravir, the backbone of a HIV franchise that generated more than $5B last year and loses patent protection between 2028 and 2030. Chief executive Luke Miels is holding a £40B 2031 sales target with 62 drugs in the clinic and 19 in late stage testing, funded partly by redeploying the savings into late stage programs and partly by the acquisitions of Nuvalent (about $11B), Rapt Therapeutics ($2.2B), Boston Pharmaceuticals ($1.2B) and 35Pharma. Job numbers were not disclosed. Shares rose about 4%, with Jefferies noting the cut was roughly double what it expected. GSK also expanded its artificial intelligence partnership with Relation Therapeutics to as much as $110M. Cutting the base and buying the pipeline is the standard patent-cliff playbook. The tell is that the R&D estate itself is being consolidated, not just headcount.

🔹 Sanofi recorded €1B in impairment charges in the second quarter, €952M of it on amlitelimab, and discontinued amlitelimab, itepekimab and balinatunfib. Itepekimab is the Regeneron-partnered interleukin-33 antibody that failed one of a pair of Phase 3 trials in chronic obstructive pulmonary disease. The commercial business is not the problem. Sales grew 17.8% in the quarter, Dupixent grew 37.6%, and full year guidance was upgraded to about 10% growth at constant exchange rates. Three months into the job, chief executive Belén Garijo is describing the plan as an R&D cleanup plus more M&A plus a China push, which is the same sequence GSK and Biogen are running. The uncomfortable read for the sector is that the assets being cut are late stage immunology antibodies at a company that owns the category’s biggest drug. If Sanofi can’t make a second wave cytokine antibody pay behind Dupixent, the bar for everyone else’s is higher than the consensus models assume.

🔹 Altimmune’s RECLAIM trial randomised about 100 patients 1:1 to 2.4 mg of pemvidutide, a glucagon/GLP-1 dual agonist, or placebo once weekly for 24 weeks in adults with alcohol use disorder. Heavy drinking days fell by 4.2 per week from baseline on drug versus 2.75 on placebo, a placebo-adjusted difference of 1.45 days at p=0.0014. Every key secondary hit: patients reaching zero heavy drinking days (p=0.0066), percentage of abstinent days (p=0.0075), and phosphatidylethanol (p<0.0001), a blood biomarker of alcohol intake that is much harder to fake than a drinking diary. Placebo-adjusted weight loss was 9.1% at 24 weeks (p<0.0001). Tolerability was described as generally favourable. The biomarker result matters more than the diary result, because self reported drinking in a trial where patients know they are being watched needs to be taken with a grain of salt. Alcohol use disorder affects tens of millions of American adults and has three approved medicines that almost nobody takes. A Phase 3 in this indication would be the first serious test of whether incretin biology reaches reward pathways rather than just appetite.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Christoph Burgstedt/Stock.Adobe.com

Solving the drug discovery crisis

More for everyone: how democratized tools can accelerate rare disease research.

Access now

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

🛒 Check out our newly launched MERCH STORE.

Subscribe now

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

Another update in the GLP-1 world this week. For two years the only question that moved stocks was how much weight a drug takes off. Lilly’s retatrutide, the most powerful weight loss molecule in development, answered that question again with two more Phase 3 wins, and the market barely cared. What the market cared about was the two harder questions that came with the data. Does the weight loss protect the heart, and did the drug hold its own prior ceiling? Both answers were underwhelming. Peak weight loss came in around 21% to 23%, below the 28.3% retatrutide posted in TRIUMPH-1, and the trial specifically run in people with cardiovascular disease couldn’t show the drug reduced heart attacks, strokes, or cardiovascular death. The regulatory filing slipped to Q1 2027. Efficacy has a visible ceiling now, and the next front is outcomes data.

That front is also a courtroom. In the same week retatrutide disappointed, Novo Nordisk sued Lilly over what it calls “maliciously and deceptively false” advertising comparing the highest doses of the two companies’ drugs. The two players who own the obesity market aren’t just competing on weight percentages and payer coverage anymore. They’re competing on what each is allowed to say about the other. When rivals move from trial design to trademark law, it usually means the clinical differentiation has narrowed enough that how you talk about the drug matters.

M&A this week kept validating on the science while raising the price question. GSK’s $10.6 billion purchase of Nuvalent, closed only a week earlier, already produced an FDA approval two months ahead of schedule for Jideytro in ROS1-positive lung cancer, GSK’s first lung cancer drug ever. In the same news cycle, the post-mortem on Vertex’s $10 billion Crinetics deal revealed that Vertex was the sole bidder and paid the second-highest premium of biotech’s banner M&A year. It was essentially bidding against itself.

Two policy stories are worth mentioning. President Trump threatened tariffs of up to 200% on generic drugs not manufactured in the United States, the first time copycat medicines specifically have been targeted, which matters far more to drug supply than the branded pharma levies did. Sartorius became the first life science company to quantify the other side of the tariff mess, cutting revenue by 26 million euros to refund customers after the Supreme Court blocked some of the earlier levies. Meanwhile Merck’s Rob Davis warned Congress that cutting off China dealmaking would cost the US its status as the world’s biotech leader. So now the biggest pharma CEOs are publicly arguing against restrictions on China deals while their own companies keep signing them.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 Novo Nordisk took Lilly to court over advertising that compares the highest doses of Zepbound and Wegovy and claims Lilly’s products are broadly superior. Novo calls the campaign “maliciously and deceptively false” and filed after a cease and desist request went nowhere. Lilly countered that its campaign is “truthful.” The lawsuit is the clearest sign yet that better clinical data is not enough to win share anymore in obesity. Lilly’s tirzepatide has generally shown deeper weight loss than semaglutide in head to head reads, which is exactly why Novo is contesting how that comparison is framed to prescribers and patients. As both franchises reach tens of $billions in revenue and the pipeline gap narrows, how each company markets against the other is now worth taking to court. Worth watching whether a court is willing to police direct drug versus drug advertising claims, which would set a precedent for every crowded category behind obesity.

🔹 The FDA approved GSK’s Jideytro (zidesamtinib) for previously treated ROS1-positive metastatic non-small cell lung cancer, GSK’s first lung cancer approval and the payoff on its largest acquisition in eight years. The clearance landed ahead of a September 18 decision date, helped by breakthrough therapy and orphan drug designations. ROS1 rearrangements appear in roughly 2% of non-small cell lung cancer, a small but well defined niche where selectivity, resistance-mutation coverage, and control of brain metastases decide the winner against existing drugs. GSK essentially bought a derisked, nearly approval asset and got revenue faster than its own model assumed, with a second Nuvalent drug, neladalkib, still under FDA review. This is the cleaner half of the M&A validation story this week. Pay up for a specific molecule near the finish line and the timeline can surprise to the upside.

🔹 The regulatory filing behind Vertex’s $10B Crinetics acquisition showed Vertex was the only company at the table and still paid the second highest premium in a year full of premiums. Analysts expect the disclosure to reignite the concern that Vertex overpaid for its largest ever deal, an endocrine pivot beyond cystic fibrosis anchored by Palsonify in acromegaly and atumelnant in late stage adrenal disease. The detail that matters is the absence of a competing bid. A 100%+ premium is easier to defend when two strategics are fighting over an asset, but it is much harder when the acquirer set the price against no one. The clinical thesis doesn’t change here, since Crinetics has a differentiated oral endocrine portfolio, but it sharpens the question of what disciplined dealmaking looks like when capital is cheap and the IPO window is wide open.

🔹Two policy stories worth mentioning this week. President Trump pledged tariffs of up to 200% on generic drugs not made in the United States, the first time generics specifically have been targeted. That is a bigger deal than the branded pharma tariffs that had limited revenue impact, because generics are where supply is thinnest, margins are lowest, and shortages are already common. A punitive import levy on copycat medicines could disrupt the drugs most Americans actually take. Separately, Sartorius cut its revenue guidance by 26M euros to refund customers for tariff surcharges it had passed on earlier in the year, after the Supreme Court blocked some of those tariffs. It is the first company to publicly quantify the financial cost of the on-again, off-again tariff policy. And Merck CEO Rob Davis warned Congress that restricting US-China dealmaking would cost the country its biotech leadership position, given how many pipeline drugs now come from Chinese licensing. Trade and China policy are quickly becoming things pharma companies have to actively plan around.

🔹 Repligen agreed to acquire cell processing supplier BioLife Solutions for roughly $1.5B, about 36% of it in stock. The interesting angle is what Repligen is buying. BioLife supplies reagents, media, and cold chain equipment to cell and gene therapy developers. So this is one tools company buying another tools company, which is essentially a bet that cell and gene therapy manufacturing volume keeps growing overall, regardless of which specific drugs succeed. BeOne (formerly BeiGene) also announced a $300M domestic manufacturing expansion the same day. Both deals show that some of the biggest checks in biotech right now are going to infrastructure.

🔹 Lilly’s retatrutide, a triple agonist that hits the GLP-1, GIP, and glucagon receptors, met the primary endpoints of both Phase 3 trials but on terms that cooled the enthusiasm. In TRIUMPH-2, the type 2 diabetes cohort, top-dose patients lost about 21% of body weight at 80 weeks. In TRIUMPH-3, run in people with established cardiovascular disease, weight loss reached roughly 22.6% to 23%. Both are strong absolute numbers and both fall short of the 28.3% retatrutide posted in TRIUMPH-1 in people without diabetes, which is the expected pattern since diabetes and cardiovascular populations typically lose less. The disappointment is the heart data. TRIUMPH-3 recorded 27 major adverse cardiovascular events on retatrutide versus 23 on placebo for the three point measure of cardiovascular death, heart attack, and stroke. So the drug didn’t demonstrate it lowers cardiovascular risk. A broader five point measure that adds all cause death and heart failure numerically favored the drug, but the sample is too small and the follow up too short to draw a clean conclusion. Lilly now plans to file with the FDA in Q1 2027, delayed for manufacturing and quality data. Retatrutide will very likely be the most powerful weight- oss drug on the market, but the industry’s next differentiator, proving the weight loss translates into fewer heart attacks and strokes, remains unclaimed. Novo’s semaglutide already carries a cardiovascular benefit label, which is precisely the ground the two companies are now fighting over in court.

🔹 Arrowhead’s RNA-interference drug plozasiran hit strong numbers in two late-stage trials in severe hypertriglyceridemia, a much larger patient population than the ultra rare familial chylomicronemia syndrome where the drug is first headed. Plozasiran cut triglycerides by a median 79% in one trial and 81% in the other at one year, versus roughly 27% in the placebo arms. A pooled analysis showed a 78% reduction in acute pancreatitis events, which is the complication that kills people with severe hypertriglyceridemia. Safety was clean, with no meaningful liver enzyme or platelet changes. The biggest practical advantage is dosing. Plozasiran is a subcutaneous injection once every three months. Ionis’s Tryngolza requires monthly injections. Arrowhead plans to file to add severe hypertriglyceridemia to the Redemplo label before the end of 2026.

🔹 Summit released longer follow up on its PD-1/VEGF bispecific ivonescimab in an effort to answer the skeptics who have questioned whether the striking Asian trial results hold up in Western patients. The updated cut of the global Phase 3 offered two year survival data with a favorable read, but the context investors most want is still missing: the direct, adequately powered comparison of benefit between Asian and Western populations. The stock has traded on this exact uncertainty all year, including a pulled secondary offering in June. Ivonescimab remains the most important test of whether Western regulators and prescribers will accept a China-originated oncology drug on data largely generated abroad, and this readout narrows but doesn’t close the gap. It keeps the idea alive that the bispecific works across populations without yet proving it.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: The Motley Fool.

Designing the therapeutic effect

Skip the ex vivo middleman. Learn how advances in in vivo medicine can accelerate drug development.

Read whitepaper

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

🛒 Check out our newly launched MERCH STORE.

Subscribe now

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

The most important approval of the week is a pill developed by Merck. The company won US FDA clearance for Lipfendra (enlicitide), the first once daily oral drug that blocks PCSK9, the protein that clears the liver’s LDL receptors. For a decade, potent PCSK9 blockade meant an injection every two to four weeks, either Amgen’s Repatha or Novartis’s twice yearly Leqvio. Merck’s version matches injectable-grade LDL cholesterol reduction in a swallowable tablet at $315 a month. This is the same mechanism delivered through a format patients actually take. The pattern repeats down the page this week. Another company reported that an oral pill grew hair in women where the standard is a topical foam, and the obesity field has spent a year migrating from injections to oral GLP1s. Convenience, not novelty, is what companies are competing on right now.

There’s an irony inside the Merck approval. It cleared in one to two months because of the priority voucher program built by former FDA Commissioner Marty Makary, whose voucher Merck collected in December. Yet in the same week, the FDA’s acting leadership publicly walked back this practice, declaring that two of his medical journal articles never constituted actual agency policy. So the agency is dismantling his methods while cashing his vouchers. Makary the person is gone, but Makary’s machinery is still approving blockbusters.

The other big theme this week is capital, and how much of it is moving. Eli Lilly bought its way into psychedelics with a $2.8 billion upfront deal for AtaiBeckley, its eleventh acquisition of 2026. AI drug discovery startup Chai Discovery raised $400 million at a $3.8 billion valuation, and radiopharma maker AdvanCell pulled in $315 million, while at least four biotechs filed to go public in two weeks. The obesity cash machine is funding an acquisition spree, the IPO window is wide open, and China-sourced assets keep flowing to Western buyers. The bear case on biotech financing that dominated 2024 and 2025 seems to have disappeared.

There's one story from this week that cuts against the optimism, though. Celcuity won FDA approval for a genuinely differentiated breast cancer drug and the stock fell almost 20%. This is a reminder that FDA approval doesn’t automatically translate to a stock move up. If the label is narrower than expected, the launch is delayed, or the prescribing information shows worse safety than the trial data suggested, the stock can still fall. Small biotechs have to clear two bars and those are the FDA and whatever expectations investors had already priced in.

BIOTECH/PHARMA NEWS 🧬

🔹 Merck’s Lipfendra (enlicitide) became the first once-daily pill to inhibit PCSK9, approved to lower LDL cholesterol in adults with high cholesterol, including inherited heterozygous familial hypercholesterolemia. It’s a macrocyclic peptide, an unusually large molecule for an oral drug, engineered to survive the gut and block a target that injectable antibodies and RNA therapies had monopolized. The efficacy is the point. In the Phase 3 CORALreef Lipids trial, enlicitide cut LDL cholesterol by a placebo-adjusted 55.8% at 24 weeks and 61.5% at one year, with a 59% reduction in the familial hypercholesterolemia study and that’s injectable-class potency. At $315 for a 30 day supply, it undercuts branded injectables and prices near generic injectable PCSK9s ($500 to $600 a month), while offering the format advantage no injectable can match. RBC Capital Markets projects more than $5B in peak annual sales. Merck earned the fast review through the priority voucher it received in December, cutting the timeline to one to two months, and beat AstraZeneca’s competing oral candidate to market. Repatha ($3B in 2025) and Leqvio now face an oral competitor with equivalent LDL lowering, and the cardiovascular outcomes data Merck is still generating will decide whether pill convenience translates into franchise displacement.

🔹 Lilly agreed to buy AtaiBeckley for $6.75 per share, about $2.8B upfront, with a contingent value right of up to $2.50 per share pushing the total toward $3.8B. The lead asset is BPL-003, a mebufotenin analog (a molecular cousin of psilocybin) in late stage testing for treatment-resistant depression, where a single dose has produced rapid symptom reduction. This is the strongest signal yet that large pharma is done watching psychedelics from the sidelines. The commercial proof point is Johnson & Johnson’s ketamine-derived Spravato, which generated almost $1.1B in the first half of 2026, up 43% year over year, showing that a scheduled, clinic-administered psychiatric drug can scale commercially. For Lilly, this is deal number eleven of 2026, more than any peer, and it continues the pattern of using obesity cash flow to buy modality and indication breadth rather than adjacent metabolic assets. Compass Pathways, the longtime psychedelics company, now has a very well-funded competitor. The open question is regulatory and logistical. These therapies require monitored dosing sessions, and reimbursement plus clinic infrastructure, not efficacy, is the gating constraint.

🔹 The FDA approved Celcuity’s Revtorpyk (gedatolisib), a pan-PI3K/AKT/mTOR inhibitor, for second-line ER-positive, HER2-negative advanced breast cancer, in combination with fulvestrant and Ibrance (palbociclib) or with Ibrance alone. The differentiated angle is that the label covers patients without PIK3CA mutations, a segment competitors from Novartis and Roche have largely left alone while focusing on the mutant population. In VIKTORIA-1, the three drug regimen delivered median tumor control of 9.3 months versus 2 months for fulvestrant alone. The two drug regimen reached 7.3 months. Yet shares fell almost 20% on two disappointments buried in the fine print. The company signaled a later launch than its prior commentary implied (now late in Q3), and the prescribing information carried higher treatment discontinuation rates than the conference data had shown. This is the recurring lesson of 2026 small cap approvals. A genuinely useful drug in an underserved niche is not automatically a good stock day when the label and the launch timeline undershoot what investors had already paid for.

🔹 Two more Western-Chinese deals landed this week. AstraZeneca agreed to pay Shanghai-based Dizal $600M upfront, up to $1.5B total, for global rights to Zegfrovy, an already marketed lung cancer drug for EGFR exon 20 insertion mutations that did about $85M in 2025 sales. Buying a derisked, approved asset rather than a preclinical one is a notable escalation of the China sourcing model. Separately, Spero Therapeutics licensed most rights to Innovent’s anti-CD40L antibody IBI355 for immune diseases, with Innovent eligible for up to $1.1B. Meanwhile, the Biotech Investment National Security Act, the House bill that would subject US biotech deals with Chinese companies to national security review, is now stalled after unsettling the industry last month.

🔹There’s a lot of biotech financing happening right now. At least four biotechs filed to go public in two weeks, including Braveheart Bio, which is funding Phase 3 testing of a Hengrui-licensed cardiac myosin inhibitor aimed at Cytokinetics and BMS, and immunology and inflammation player Attovia. On the private side, AI structure prediction startup Chai Discovery raised $400M at a $3.8B valuation, the second-largest venture round tracked this year. Radiopharma maker AdvanCell closed a $315M Series D for a lead-based Pluvicto challenger, with Lilly and Sanofi both participating. Lipid nanoparticle startup Nava emerged with $89M. Investors are cutting big checks for early- tage companies in AI, radiopharma, cardiac disease, and gene delivery, and the IPO market is opening back up at the same time. Biotech financing hasn't looked this healthy since 2021.

🔹 The FDA’s acting chief formally walked back former Commissioner Marty Makary’s practice of setting policy through medical journal articles, stating that two such articles published over the past year did not represent agency policy. It’s the latest in a steady reversal of Makary-era actions since his departure in May, and it sharpens the strategic uncertainty for sponsors who had read those articles as signals of the review bar. The timing is worth pointing out. In the same week the agency said Makary’s journal articles were never actual policy, Merck’s oral PCSK9 approval came through on the fast track that Makary himself set up. So companies planning regulatory strategy have to figure out which parts of the Makary era still count. The voucher program and formal guidance clearly do. Informal signals from journal articles clearly don't. And the FDA still doesn't have a permanent commissioner three months in.

🔹 Kelun-Biotech’s TROP2 antibody-drug conjugate sac-TMT, partnered with Merck, hit its primary endpoint in Phase 3 OptiTROP-Lung06, a China trial testing sac-TMT plus Keytruda as first-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer with PD-L1-negative tumors. The combination showed a statistically significant, clinically meaningful improvement in progression-free survival versus standard chemotherapy, with an early positive trend in overall survival. Specific hazard ratios weren’t disclosed at the interim. This matters because PD-L1-negative patients respond poorly to immunotherapy alone, and this trial shows for the first time that an antibody-drug conjugate could anchor a first-line lung cancer regimen without chemotherapy in that group. It’s also the second Chinese trial to work for Merck’s sac-TMT program this year, after OptiTROP-Lung05 in May. Merck now has 17 Phase 3 studies running across breast, lung, gastrointestinal, genitourinary, and gynecological cancers. The open question is whether Western regulators will accept the survival curves from a China-only trial without a global confirmatory study.

🔹 Veradermics reported that its extended-release oral formulation of minoxidil, the active ingredient in Rogaine, worked in women with mild-to-moderate pattern hair loss. Across 28 women dosed once or twice daily for six months, the drug produced a mean increase of about 23 hairs per square centimeter, beating the 15 to 20 analysts had projected, with most patients reporting visible improvement by two months. Shares jumped toward $130 before settling near $116. The extended-release design is meant to sustain drug exposure and avoid the concentration spikes that drive side effects. If this holds up, it could become the first pill specifically approved for female pattern hair loss, a condition affecting roughly 30M American women by some estimates, replacing daily topical foam with a tablet. That said, this is a small single arm signal in only 28 patients with no head-to-head comparison, so the data is encouraging but far from definitive. Phase 3 data in men is expected in the second half of 2026 and the women’s Phase 2/3 in the first half of 2027. Absci’s AI-designed hair loss antibody, backed by Lilly, is the longer-dosing-interval competitor to watch alongside this.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Getty Images

Last week, I launched the Biotech Blueprint merch store. The limited subscription special is running for one more week (ends July 16). Sign up for annual subscription and pick a free T-shirt of your choice. Visit the store at https://biotechblueprint.printify.me/ to see available designs, colors, and sizes.

Subscribe now

Give a gift subscription

Democratizing drug development

From bespoke labs to systemic change. Explore tools to accelerate in vivo genomic medicine development.

View paper

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

Subscribe now

VIDEO SUMMARY

The video recording platform didn’t record the first few seconds so apologies and Welcome back to Biotech Blueprint :)

THIS WEEK’S KEY TAKEAWAYS 🔑

The biggest story this week was a failure. AstraZeneca and Ionis’s eplontersen missed the primary endpoint of the Phase 3 CARDIO-TTRansform trial in transthyretin amyloid cardiomyopathy, a fatal heart-muscle disease. The market reaction told the story. AstraZeneca fell 8%, Ionis fell 21%, and rivals Alnylam and BridgeBio both jumped double digits. What actually happened is that the standard of care caught up to the trial. By the time CARDIO-TTRansform read out, 57% of patients were already on a protein-stabilizer drug (Pfizer’s Vyndamax or BridgeBio’s Attruby) at baseline, and another 24% started one during the study. Eplontersen worked (29% risk reduction) only in the shrinking group taking nothing else. In transthyretin amyloid cardiomyopathy, a fourth entrant now has to beat a background of drugs that already work, not placebo. Alnylam and BridgeBio didn’t win because they ran a better trial this week but because they were already on the field.

Vertex spent $10 billion this week, its largest deal ever, to buy Crinetics and move beyond the cystic fibrosis franchise that still generates more than $10 billion a year. The same dynamic showed up in kidney disease, where Vera Therapeutics won accelerated FDA approval for Trutakna (atacicept) in immunoglobulin A nephropathy, the second drug of its kind to market after Otsuka’s Voyxact, but with the deeper dataset and a higher price. In both cases the message is the same. Being first is worth less than being better and payers will price the difference.

Two other themes worth flagging this week. First, obesity is truly shifting from an efficacy story to a tolerability story. Kailera and Hengrui’s oral GLP-1 pill hit its Phase 3 goals in China but with nausea and vomiting rates near 70%, which one analyst called alarming. Second, the pace of Western deals with Chinese biotechs isn't slowing down, even as Washington moves to restrict them. AstraZeneca and GSK both signed deals with Sino Biopharmaceutical this week, adding to roughly 100 Western-Chinese transactions since early 2025, the exact pattern that new legislation is trying to slow.

Finally, individualized medicine got real money. ARPA-H committed up to $160 million to seven labs to build custom gene-editing treatments for rare diseases, an attempt to turn the one-off “Baby KJ” success into a repeatable process. In the same week, Prime Medicine won an arbitration ruling against Beam that clears its lead gene-editing program to keep moving. Custom, one-off gene editing is starting to move from proof of concept to actual funded infrastructure.

Biotech/Pharma News 🧬

🔹 Vertex agreed to acquire Crinetics for $85 per share in cash, a 102% premium and the fourth largest biotech acquisition of 2026. The two endocrine drugs Vertex is buying are Palsonify (paltusotine), an oral therapy for acromegaly approved in September 2025 that pulled in $10M in Q1 revenue and is pacing toward roughly $70M this year, and atumelnant, a late stage candidate for congenital adrenal hyperplasia and Cushing’s syndrome. Vertex projects combined peak sales above $5B. This is the clearest statement yet that Vertex intends to become a multi-franchise specialty company rather than the cystic fibrosis only company it has been, adding endocrinology to recent moves in pain (Journavx) and kidney disease. Not everyone loved the price. Stifel called the deal a bet on the “bullish case,” flagging competition from Pfizer and Novartis on the acromegaly side and Neurocrine’s Crenessity against atumelnant, and Vertex stock ticked down on the news. Vertex is sitting on cystic fibrosis cash and facing eventual competition there, so the calculation is that overpaying for de-risked commercial and near-commercial assets today beats waiting. Closing is expected in Q3.

🔹 The FDA granted accelerated approval to Vera Therapeutics’ Trutakna (atacicept) to reduce proteinuria in adults with primary immunoglobulin A nephropathy, a progressive kidney disease affecting about 160k Americans. Trutakna is a once weekly self-injected antibody that blocks two immune signals, BAFF and APRIL, and is the first approved drug to hit both. In the ORIGIN 3 trial it cut urine protein 46% from baseline at 36 weeks, a 42% reduction versus placebo. Because this is accelerated approval based on a surrogate endpoint, Vera still has to prove the drug preserves kidney function over time, with confirmatory data expected in Q3. The commercial fight is a head to head with Otsuka’s Voyxact, which reached market last year and targets APRIL alone with monthly dosing. Vera priced Trutakna at $425k a year against Voyxact’s roughly $390k, betting that a broader mechanism and a stronger dataset justify the premium. Two drugs competing on data quality and dosing convenience rather than novelty is the market Vera has just entered.

🔹 GSK terminated its neurodegeneration alliance with Alector, ending a partnership once worth up to $2.2B (including a $700M upfront in 2021). Both assets failed. Latozinemab, a progranulin-boosting antibody for frontotemporal dementia in patients with specific mutations, failed to slow disease in its late stage trial last October, and Alector halted a Phase 2 study of nivisnebart in early Alzheimer’s on a futility analysis in April. The collapse is a real setback for GSK’s tentative return to brain diseases after more than a decade on the sidelines. For Alector it’s closer to a survival question. The company also lost a separate AbbVie collaboration, has cut staff repeatedly, and has seen its stock fall about 95% over five years. Progranulin biology has been one of neurology’s more credible genetic hypotheses for years, but it hasn’t translated into a disease-modifying win, and large cap partners are no longer willing to keep paying to find out.

🔹 Two of the biggest UK drugmakers signed China deals in the same week. AstraZeneca paid $200M upfront, with up to $1.9B in milestones plus royalties, for ex-China rights to TQC3721, a Sino Biopharmaceutical inhaled lung drug that has cleared Phase 2 in chronic obstructive pulmonary disease with better lung function than standard therapy. That positions AstraZeneca against Merck’s Ohtuvayre, which Merck acquired by paying $10B for Verona Pharma. GSK separately handed Sino the China rights to distribute its marketed respiratory drugs Trelegy (£3 billion in 2025 global sales) and Anoro. These deals land in the middle of roughly 100 Western-Chinese pharma deals since early 2025, and the exact scrutiny that count has provoked. Proposed US legislation would subject outbound investment in Chinese biotech to national-security review. Even as policymakers try to slow the China licensing channel, the economics keep winning. Faster, cheaper, later-stage assets are enough for big pharma to keep signing.

🔹 MeiraGTx secured up to $400M from Oberland Capital in a royalty and financing arrangement to support its late stage eye gene therapies, one of which it recently reacquired from Johnson & Johnson (bota-vec, for X-linked retinitis pigmentosa). The interesting part is the structure. This is another example of revenue and launch-stage biotech reaching for non-dilutive private capital (royalty monetization, structured credit) rather than selling shares, even with public markets wide open. It follows the same logic as BridgeBio’s $1B preferred equity for its amyloidosis launch and Blackstone’s royalty deals. For companies with visible commercial catalysts, giving up future royalties looks cheaper than giving up equity today.

🔹 ARPA-H committed up to $160M through a program called THRIVE to seven research teams building custom gene-editing treatments for rare diseases across multiple organ systems, with the teams required to reach the clinic by year three. THRIVE is an explicit bet that the widely covered “Baby KJ” case, in which an infant received a one of a kind editing therapy, can become a repeatable manufacturing and regulatory pathway rather than a single exception. Custom, N of 1 gene editing has been the frontier the field has been circling for years. Federal money is now trying to industrialize it.

🔹 The White House is reviewing three finalists to run the FDA, suggesting a decision may finally be near after months without a permanent commissioner since Marty Makary’s May departure. In parallel, the agency paused its practice of publicly releasing the letters that explain why it rejects drugs, following a citizen petition from an unnamed pharma company, while it works to formalize the policy. The transparency reversal is small but telling. The short-lived experiment in publishing complete response letters, meant to demystify rejections, is on hold. And the leadership vacuum that has shadowed PDUFA timing all summer may soon lift. Both matter for how predictable the regulatory path looks in the back half of 2026.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: ChatGPT

Today, we’re launching the Biotech Blueprint merch store.

To celebrate, we’re running a limited subscription special: sign up for annual subscription and pick a free T-shirt of your choice. After subscribing, please send us your mailing address, preferred T-shirt design, color, and size.

Offer ends Thursday, July 9 at midnight.

HAPPY 4TH! 🎆

Subscribe now

Give a gift subscription

Visit our store https://biotechblueprint.printify.me/ to see available designs, colors, and sizes:

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

The most important number this week is one Roche didn’t release. Its KRAS G12C inhibitor divarasib beat both approved drugs in the class, Amgen’s Lumakras and Bristol Myers Squibb’s Krazati, in a single Phase 3 trial, improving both overall survival and progression-free survival in previously treated lung cancer. The company held back the actual hazard ratios for a medical meeting, but the design is the story. Roche didn’t run against placebo or chemotherapy but it ran against the two incumbents at once and won. That’s now the third head to head superiority readout in seven weeks, after Takeda’s zasocitinib topped Bristol Myers’ Sotyktu in psoriasis and Akeso’s ivonescimab beat an active PD-1 inhibitor in lung cancer. Beating standard of care used to mean beating whatever came before the current drugs. Now it increasingly means beating the current drugs, and sponsors who are confident in their molecule are choosing to prove it directly rather than lean on cross trial comparison.

The SPDR S&P Biotech ETF (XBI) is up about 30% year to date and rose roughly 19% in June alone, a five-year high that’s closing in on the February 2021 peak of 175. BridgeBio pulled in up to $1 billion in structured capital to fund a commercial launch without selling common stock at a discount. Abivax cleared a cancer safety cloud, watched its shares jump about 40%, and raised $800 million the same week. Ipsen bought two clinical stage biotechs in three days. When the market is this strong, companies aren’t fighting to raise money anymore. They’re fighting to execute, which happens to be the environment that rewards clean head to head data.

The week’s structural signal came from outside pharma. Anthropic launched Claude Science, an AI research workbench aimed squarely at drug company research operations, and disclosed that it will start discovering its own drugs, beginning with neglected diseases the industry ignores. Isomorphic Labs and Recursion have been on this arc for years, but they were biotech native startups.

Underneath everything else, cell and gene therapy kept quietly racking up approvals. Vertex’s Casgevy became the first gene therapy cleared for children as young as two with sickle cell disease. The FDA approved TREGZI, the first regulatory T cell therapy for chronic graft-versus-host disease. United Therapeutics bought a thymic cell therapy platform. None of these was a blockbuster event by itself, but together they show the pattern. The modalities that Section 232 tariffs exempt are also the ones the agency keeps clearing without drama.

Biotech/Pharma News 🧬

🔹 The FDA approved Viridian Therapeutics’ Lumvoa (veligrotug) for thyroid eye disease, and the label is the prize. Like Amgen’s Tepezza, Lumvoa targets the insulin-like growth factor 1 receptor, the inflammation driver behind the disease. But the approval covers both active and chronic thyroid eye disease, where Tepezza’s indication is narrower, and Lumvoa’s regimen is five 30 to 40 minute infusions every three weeks against Tepezza’s eight infusions of up to 90 minutes each. Jefferies pegs pricing near $450k, comparable to Tepezza, so Viridian isn’t buying share with a discount. It’s offering the same mechanism with a lighter treatment burden and a wider label. Leerink’s Thomas Smith argued the combination could expand the treated market rather than just split it. Amgen now has to defend Tepezza against a cleaner competitor, with Immunovant’s subcutaneous IGF-1R candidate still behind them both.

🔹 Ipsen bought Memo Therapeutics for about $800M, roughly €200M upfront plus more than €500M in milestones, for potravitug, an antibody against BK polyomavirus in kidney transplant patients. There’s no approved targeted treatment for the virus, potravitug showed viral suppression and nephropathy resolution in Phase 2, and a pivotal Phase 2/3 trial is expected to start later this year. Two days earlier Ipsen agreed to buy Kartos Therapeutics for $450M upfront and up to $1.3B in milestones, adding a late stage myelofibrosis asset. Ipsen’s rare disease unit generated only about €384M in 2025 against €2.5B+ in oncology, so this is Ipsen deliberately building a third leg. Two deals in a week fits the pattern of European mid-caps assembling clinical inventory ahead of the July 31 Section 232 tariff date.

🔹 Anthropic released Claude Science, a research workbench that connects to more than 60 scientific databases and ships with toolkits for genomics, protein structure analysis, and chemistry, pitched to pharmaceutical research teams the way Claude Code was pitched to software teams. Anthropic will also begin discovering its own drugs, starting with neglected diseases that traditional developers avoid, and demonstrated the system autonomously proposing candidates for phenylketonuria, a rare metabolic disorder. So the largest AI model maker is now competing with its own customers, at least in one narrow segment. It’s a low stakes entry, since neglected diseases carry little commercial threat to pharma companies, but the bigger message is that Anthropic thinks its tools are ready to run the discovery process end to end, not just help someone else do it faster. The credibility test is still a clinic-ready candidate, and the first AI-originated Phase 1 readouts are expected around the end of 2026.

🔹 Abivax released additional Phase 3 safety data showing that malignancy rates for obefazimod, its oral ulcerative colitis candidate, matched background rates for ulcerative colitis patients generally across more than 1,700 patient years of exposure. That directly addresses the cancer cases at the highest dose that crashed the stock in June. Leerink’s Thomas Smith concluded there was “no real malignancy signal” beyond the elevated cancer risk this population already carries from chronic inflammation. Shares surged nearly 40%, and Abivax used the reopening to complete an $800M offering, with an FDA filing planned by year end. The company has drawn reported takeover interest it publicly downplays. Obefazimod’s remission data (roughly 51% versus 10% placebo in maintenance) were never the question. The safety data was, and it just got answered.

🔹 Three separate cell and gene therapy actions extended the modality’s momentum this week. Vertex’s Casgevy became the first gene therapy approved for children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia, pushing the CRISPR therapy into a younger population. The FDA approved TREGZI, the first regulatory T cell (Treg) immunotherapy, to improve chronic graft-versus-host disease-free survival in blood cancer patients receiving allogeneic stem cell transplants. And United Therapeutics bought Thymmune for $140M upfront plus up to $160M in milestones for THY-100, a cell therapy that converts stem cells into thymic cells to restore T cell production in congenital athymia. Individually minor but together they confirm that the tariff exempt modalities keep clearing the agency while conventional biologics wait on the Section 232 clock.

🔹 Roche’s oral KRAS G12C inhibitor divarasib beat both Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in previously treated non-small cell lung cancer patients whose tumors carry the KRAS G12C mutation, which appears in about 14% of cases. The Phase 3 Krascendo-1 trial reported statistically significant improvements in both overall survival and progression-free survival against the two approved comparators, with no new safety findings and side effects described as manageable and reversible. The specific hazard ratios were deferred to an upcoming medical meeting, which is the one caveat. Without the magnitude, it’s too early to say whether this is a modest edge or a class reset. What isn’t in doubt is the design choice. Roche took on both incumbents simultaneously and cleared them on the hardest endpoint. The bigger prize is Krascendo-2, testing divarasib plus Keytruda in the first-line setting, where the market is far larger. Winning second-line sets Roche up. First-line is where they’d actually take the class.

🔹 Otsuka’s Voyxact stabilized kidney function and showed evidence of improvement after two years versus placebo in IgA nephropathy, completing the dataset required for traditional (rather than accelerated) approval. IgA nephropathy has become one of the more crowded rare disease races, and the two year confirmatory readout matters because it converts a surrogate-based accelerated pathway into durable clinical evidence. That’s exactly the surrogate to clinical translation the FDA has been demanding across programs this quarter. For Otsuka, it’s a reminder that its nephrology franchise is quietly delivering the long term data that separates approvable from durable.

🔹 BridgeBio raised up to $1B in preferred equity from Sixth Street Partners ($800M) and HealthCare Royalty ($133.9M) to fund the commercial push behind Attruby (acoramidis) in transthyretin amyloid cardiomyopathy. The structure carries a 7% initial preferred dividend, with a conversion price starting at $137.79 per share and stepping up to $153.10 after five years. The reason this matters isn’t the size of the raise but the structure. BridgeBio didn’t sell common stock into the market and dilute existing shareholders. It borrowed against future cash flows to scale its commercial reach. That’s the same structured capital playbook Blackstone ran with Apogee in May, but applied to a company that already has a drug on the market. When you’re already selling a product, nondilutive financing beats a cheap equity raise every time, even when the equity window is open.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Yahoo Finance

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

You could watch the central tension of this week play out on a single day. On Monday, the Department of Health and Human Services published a blueprint called Operation TrialBlazer, designed to pull early stage drug research back onto US soil and close the roughly 18 month head start China holds in moving a molecule from discovery into the clinic. Two days later, Lilly committed up to $1.9 billion in a multi target discovery deal with Abbisko, a Shanghai-based biotech. Washington is trying to make US drug development faster while the money keeps flowing to the place that’s already fast.

What’s changed is that Washington has stopped trying to only wall China off and started trying to outcompete it. The 2024 Biosecure Act didn’t slow China’s rise and lawmakers know it. So the response this week was about making US development more attractive, not punishing companies for working with China. Operation TrialBlazer promises clearer FDA expectations before an investigational new drug filing, fewer redundant toxicology requirements, more flexible trial protocols, and a consultation pilot to speed institutional review. Scott Gottlieb, the former FDA commissioner, put it plainly: “the time and cost advantage can’t tilt so heavily against US-based trials or we’ll lose our edge.” The thing nobody wants to say out loud is that it already has tilted, and a blueprint isn’t going to rebuild a clinical trial ecosystem in a quarter.

The deals from this week tell you where speed actually lives right now. Lilly-Abbisko was the headline, but Ollin Biosciences raised $330 million to push a China-licensed challenger to Roche’s Vabysmo through Phase 3, and Serapha Bio launched on a China-sourced in vivo base-editing program. US and European pharma keep buying de-risked, fast moving chemistry from Chinese developers, while US policy scrambles to make domestic development competitive enough that the next generation of those molecules originates here instead. Both dynamics are running in parallel, and this week they were running right next to each other.

The other thread worth pulling on is Lilly itself, which appeared in three separate deals in five days: the $1.9 billion Abbisko pact, a $40 million equity check into AI design startup Absci, and a $50 million stalking horse bid for the platform assets of bankrupt Sangamo. Lilly is reconstructing its pipeline faster and more opportunistically than anyone else in the industry. Underneath all the deal flow is a quieter macro fact that’s worth holding onto: US health spending hit $5.7 trillion in 2025, up 7.3%, with GLP-1 demand explicitly named as a driver. The bill for the obesity revolution is now showing up in the national accounts, and that’s the backdrop everyone in this space has to operate against.

Biotech/Pharma News 🧬

🔹 HHS published a reform blueprint called Operation TrailBlazer on June 23 built around one competitive problem. A US drugmaker can take far longer than 18 months to move a molecule from discovery into a clinical trial, while China routinely does it inside that window. The proposed fixes are procedural but real. The FDA would specify required data before an IND filing to cut redundant toxicology and chemistry work, allow more flexible trial protocols to reduce amendment filings, and run a consultation pilot that lets developers engage research institutions during IND preparation. NIH would push telehealth, remote monitoring, real-world data, and AI to widen enrollment into rural and underserved areas. There’s even an examination of whether trial participant stipends beyond expense reimbursement are legal under anti kickback rules. The 2024 Biosecure Act tried to slow China down by restricting access. This blueprint takes the opposite approach and tries to make US drug development competitive enough that companies don’t need to look abroad. Whether it actually works depends on execution inside an FDA that has cycled through multiple commissioners and senior reviewers over the past few months, which is exactly the kind of capacity that procedural reform assumes is intact.

🔹 Lilly agreed on June 23 to pay Abbisko Therapeutics an undisclosed upfront plus up to $1.9B in milestones, with tiered royalties, for discovery and early development across multiple undisclosed targets. The deal builds on a 2022 small molecule collaboration between the two companies, so this is a continuation. The timing matters. Hours after the HHS blueprint announcement, the most acquisitive company in pharma chose to widen its bet on Chinese discovery chemistry instead of pulling work back to the US. Abbisko, based in Shanghai, runs the discovery and early development. Lilly holds the development and commercial economics. It’s the same licensing arbitrage model that BMS-Hengrui, Pfizer-Kailera, and Merck-Terns institutionalized over the past year, except now it carries added regulatory timing risk as lawmakers lay the groundwork for legislation that would mandate Treasury and Defense review of pharma deals with Chinese counterparts.

🔹 Novartis ran the domestic version of the same playbook on the same day, paying Antares Therapeutics $105M upfront and up to $1.8B in milestones, plus royalties, to generate small molecules against historically undruggable oncology targets. Antares is exactly the kind of US story Operation TrialBlazer is rooting for. It spun out of Scorpion Therapeutics in June 2025 with $177M in funding, after Scorpion sold a drug program to Lilly for up to $2.5B. Scorpion built its reputation by finding hidden binding pockets, including on PI3K-alpha, and Antares carries that toolkit forward. Its lead oncology program is expected to enter human testing in 2026. Put Novartis-Antares next to Lilly-Abbisko and you get the week’s competitive map in two transactions. Big pharma will pay roughly the same nine figure upfront and ten figure biobucks for fast discovery chemistry whether it sits in Boston or Shanghai.

🔹 Sangamo Therapeutics, one of the original zinc-finger gene-editing companies, filed for Chapter 11 in Delaware on June 23 and lined up initial buyers to anchor an auction of substantially all its assets. Lilly agreed to pay $50M plus assumed liabilities for Sangamo’s capsid delivery platform, zinc-finger platform, modular integrase platform, and its ST-506 prion disease program. Astellas separately agreed to $25M at closing plus up to $25M in milestones for the Fabry disease program ST-920. This is the gene therapy shakeout playing out as a fire sale. A foundational platform company that couldn’t fund itself through to commercial value, with its technology getting absorbed by deep pocketed buyers at distressed prices. For Lilly, $50M buys an entire delivery and integrase toolkit to feed its expanding genetic medicine ambitions, the kind of price only available when the seller is in bankruptcy court.

🔹 Lilly also led a $100M stock offering in Absci, buying $40M of equity. The 13.5M shares priced at $7.41, and Absci shares surged on the news alongside accompanying early clinical data. The money funds ABS-201, an AI-designed antibody being developed for both pattern hair loss and endometriosis. The asset’s selling point is durability. It showed a long lasting presence in the body, which could mean only a few injections per year, a meaningful convenience advantage in a cash pay aesthetic category. Initial proof of concept hair loss data are expected in the second half of 2026, with fuller results in early 2027. For Lilly this is a small optionality bet that checks two boxes the company clearly cares about, AI-driven drug design and a large consumer paid market, for the price of a rounding error.

🔹 US national health expenditure reached $5.7 trillion in 2025, a 7.3% increase and nearly $16,500 per person, according to figures published in Health Affairs on June 24. Government actuaries flagged hospital services and high priced prescription drugs, with GLP-1s explicitly named, and noted that utilization rather than unit price growth is what’s accelerating the trend. Spending is projected to top $6 trillion in 2026, with prescription drug outlays alone expected to exceed $560B next year, up 8.2% and growing faster than any other major category. The obesity drug boom is now showing up in the national accounts, not just in Lilly’s and Novo’s revenue lines. That shifts the political and payer conversation from whether these drugs work to who pays for what is becoming a permanent multi hundred billion dollar line item. The affordability constraint that has been building all year now has a federal number attached to it.

🔹 Pfizer’s sigvotatug vedotin, an integrin beta-6 targeting antibody-drug conjugate, failed its Phase 3 trial in second-line non-squamous non small cell lung cancer. The drug didn’t meaningfully extend overall survival versus docetaxel chemotherapy. Pfizer deferred specific numbers to a future medical meeting. The target was attractive on paper, since integrin beta-6 is expressed on roughly 90% of tumors, but a miss against standard chemotherapy is a miss. This is also a Seagen asset, and Pfizer has now absorbed about $4.5B in write offs tied to Seagen-acquired programs. The readout cuts deeper than one trial. It raises real questions about the return on Pfizer’s $43B Seagen acquisition. The drug’s surviving shot is a first-line combination with Keytruda, with data expected in 2027 in a different comparator and patient population. Early-line combinations sometimes rescue ADCs that have failed as monotherapy in later lines, but that’s a 2027 question now, not a 2026 one.

🔹 Two smaller deals reinforced the China-sourcing pattern this week. Ollin Biosciences raised $330M in a Series B to push a China-licensed challenger to Roche’s Vabysmo through Phase 3 in retinal disease. Vabysmo is one of Roche’s biggest growth products, used to treat wet age-related macular degeneration and diabetic macular edema, and brought in over $3B last year. Separately, Serapha Bio launched this week with a Series A focused on in vivo base-editing programs licensed from Chinese developers, building on the same lipid nanoparticle delivery approach Intellia validated in hereditary angioedema and Verve is extending in cardiovascular disease. Both companies are using the same playbook that defined this week. US capital plus Chinese discovery chemistry, pushed through Western regulatory and commercial channels. The launches don’t move the market on their own, but they show the licensing arbitrage model isn’t just happening at the large-cap level. It’s now the default starting position for new US biotech entrants too.

🔹 A more uncomfortable Lilly story closed out the week. Back in April, the FDA and Lilly granted compassionate-use access to retatrutide, the company’s not yet approved triple-G obesity drug, for a 79 year old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension. The application was filed by a senior NIH clinician and drew interest from top health officials, which was unusual enough that Senator Maggie Hassan wrote to HHS Secretary Robert F. Kennedy Jr. asking whether the patient was President Trump or someone close to him. The White House said after publication that the application was not for the president. The patient’s identity is still unconfirmed. The compassionate-use pathway is meant for serious, immediately life threatening conditions, and the controversy is less about retatrutide itself than about whether access to experimental medicines runs through clinical need or political proximity. It’s a reputational footnote for the drug today, but a live question about how the FDA’s expanded-access discretion gets used.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Alex Hogan/STAT

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

The most interesting thing that happened this week wasn’t a clinical readout or a deal. It was the FDA reversing itself on two products in two days. On Wednesday, uniQure said the agency will accept three year data from a roughly 50 patient Phase 1/2 study as the primary basis for an accelerated approval filing of AMT-130, its gene therapy for Huntington’s disease. The FDA had previously asked for more. A day later, the agency’s vaccines advisory committee voted unanimously that Moderna’s mRNA flu vaccine has a favorable benefit-risk profile, for a product the same agency had refused to even review earlier this year. Both reversals came after Marty Makary and Vinay Prasad left.

It would be easy to read this as the FDA going soft. It’s not. Under acting commissioner Kyle Diamantas, the agency is being selectively flexible on programs where there’s no current alternative. There’s nothing approved for Huntington’s, which is a uniformly fatal disease. mRNA gives the US a faster way to update flu vaccines as strains drift. But in other areas, the bar hasn’t moved at all. Fulcrum’s sickle cell program got sidelined last week on a safety question, and AstraZeneca’s camizestrant in breast cancer is still frozen after a negative advisory vote in April. So the agency isn’t lowering its standards across the board but it seems to be making case by case decisions about where unmet need is high enough to accept less data. For developers, that makes regulatory strategy harder to plan, because the rules now depend on which category your program lands in.

The other big theme is that M&A keeps happening every single week. Biogen bought an immunology startup for up to $1 billion. Jazz signed a T cell engager deal worth up to $4.1 billion. Lilly bought a non-opioid pain developer in what’s now their fifteenth deal of 2026. PwC reported first quarter pharma deal value above $65 billion and called the biopharma ecosystem “back to full health.” Large caps are buying discovery speed and modality breadth instead of building it in house, and they’re doing it before Section 232 pharma tariffs kick in on July 31.

The IPO market is the cleanest bull signal in biotech right now. Kardigan raised $400 million in an upsized offering this week and closed up 38% on its first day of trading. That makes four biotechs to raise at least $400 million via IPO in 2026, the most in any single year since 2021.

BIOTECH/PHARMA NEWS 🧬

🔹 uniQure said the FDA will accept three year data from its Phase 1/2 study of AMT-130 as the primary basis for a Biologics License Application under accelerated approval. The company plans to file in Q3 2026. AMT-130 is an AAV gene therapy delivered directly into the striatum via neurosurgery, designed to lower the mutant huntingtin protein that drives Huntington’s disease. There is no approved therapy for Huntington’s, which makes a filing on a roughly 50 patient dataset a clear signal that the agency will accept a small package when the disease is fatal and untreated. The FDA also indicated it’s open to a concurrent standard of care control in the confirmatory study rather than a sham surgical arm, which is a meaningful concession given the ethics and cost of sham neurosurgery. Shares jumped on the news. The open questions are durability of effect and whether a 50 patient base can carry a label in a heterogeneous, slowly progressing disease.

🔹 The FDA’s vaccines advisory committee voted unanimously that the benefit-risk profile of mFluSiva, Moderna’s mRNA trivalent seasonal flu vaccine, is favorable. The FDA target decision date is August 5. This completes a striking turnaround. The same agency declined to review the same shot earlier this year, and the briefing documents released ahead of the meeting were supportive. If approved, mFluSiva would be the first mRNA-based seasonal influenza vaccine in the US. The practical implication is that mRNA’s core advantage, speed of reformulation against drifting strains, finally gets a US regulatory anchor in flu, the largest vaccine market by volume. For Moderna, this is the proof point that the platform extends beyond COVID. Vaccine politics remain the wild card between a unanimous panel and a final signature.

🔹 Jazz Pharmaceuticals and AbCellera signed a collaboration to discover next-generation T cell engaging multispecific antibodies for gastrointestinal and other solid tumors. AbCellera takes $56M upfront across the first two programs, plus $28M on initiation of a third, with up to $792M per program in option and milestone payments and tiered royalties, totaling up to $4.1B across as many as five programs. T cell engagers have largely worked in blood cancers and struggled in solid tumors, where the targets are less clean and the toxicity harder to manage. Jazz is paying for AbCellera’s antibody engineering platform to solve that problem rather than buying a finished asset. The small upfront and heavily backloaded structure is the standard template for platform deals where the science still has to prove itself.

🔹 Biogen agreed to acquire RayThera, a private developer of small molecule anti-inflammatory drugs, for up to $1B in upfront and primarily clinical and regulatory milestones. The lead candidate is expected to enter Phase 1 in early Q3 2026. This is Biogen’s second sizable deal of the year after the roughly $5.6B Apellis acquisition in March, and it continues a deliberate push into immunology as the company diversifies away from a neurology franchise that has produced two Phase 2b misses in twelve months. The deal structure, small disclosed upfront with most of the value contingent, fits a preclinical stage asset. What Biogen is really buying is optionality in immune-mediated disease at a price that limits downside if the lead program stalls.

🔹 Lilly acquired 4E Therapeutics, an Austin neuroscience company developing oral MNK inhibitors for chronic pain, on undisclosed terms. The lead compound, 4ET1103, targets the MNK-eIF4E signaling pathway in peripheral sensory neurons and is the first MNK inhibitor for pain to reach the clinic. This is Lilly’s second non-opioid pain acquisition in as many years, following the up to $1 billion SiteOne deal in May 2025, which targeted sodium ion channels. It’s also their fifteenth or so deal of 2026 and pushes the year’s committed acquisition capital past $18B. The chronic pain market has been waiting two decades for a credible alternative to opioids, and Lilly is now building optionality across multiple non-opioid mechanisms.

🔹 Kardigan, a cardiovascular drug developer founded by former MyoKardia executives, raised $400M in an upsized IPO, selling 25M shares at $16, the top of its range. Shares closed up 38% at $22, giving the company a market value near $2B. MyoKardia developed Camzyos and was acquired by Bristol Myers Squibb for $13B, so the founder pedigree is direct. Kardigan has now raised close to $1B total in two years, including a $254M Series B in October. It’s the fourth biotech to raise at least $400M via IPO this year, the most in a single year since 2021. The 38% pop on debut is the signal worth watching. The 2026 IPO class is holding its value in the aftermarket, which is what separates a real funding window from a temporary one.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: pharmaphorum.com

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

This week belonged to metabolism. The American Diabetes Association meeting in New Orleans pushed the obesity conversation into a new phase. For three years the story has been Lilly versus Novo and this week it became a four player field. AstraZeneca put real Phase 2 numbers behind its oral GLP-1 pill elecoglipron, 10.5% weight loss at 26 weeks rising to 11.8% at 36 with no plateau, and committed to a sprawling Phase 3 program anchoring what it now frames as a $5 billion cardiometabolic franchise. AstraZeneca is now the third large cap with a credible oral incretin in pivotal development, behind Lilly’s Foundayo and alongside Pfizer’s Metsera assets. The efficacy isn’t class leading, but you don’t need to be best in class to compete in this market anymore. You just need to be good enough, which says a lot about how big the opportunity has become.

The most important obesity development this week wasn’t about a drug. More US employers are planning to drop GLP-1 coverage for weight loss in 2027 because too many of their employees are taking the drugs. Real world persistence is the problem nobody likes to talk about: adherence falls from 65% at 120 days to 34% at one year. The efficacy race, retatrutide at 28.3% in 80 weeks, CagriSema at 23% in 84, is happening on top of a reimbursement system that’s starting to give way. The next phase of this market isn’t about who loses the most weight, but who can stay on the drug long enough, and affordably enough, for the weight loss to matter.

Outside of obesity, the week had its share of platform wins and program failures. Novartis got an early payoff from its $12 billion Avidity acquisition with a clean biomarker win for an antisense oligonucleotide conjugate in muscular dystrophy, then doubled down on molecular glues with a second Orionis deal. Takeda’s zasocitinib beat BMS’s marketed Sotyktu head-to-head in psoriasis, the first time one TYK2 inhibitor has shown statistical superiority over another. Meanwhile Sanofi halted a Phase 3 in a rare neuropathy for insufficient efficacy, and Gilead and Merck’s Trodelvy plus Keytruda combination missed in lung cancer even as their once weekly HIV pill succeeded.

Parabilis priced the largest venture-backed biotech IPO in history at $670 million, beating Kailera’s $625 million record from two months ago. The same week, Summit Therapeutics pulled a $500 million share sale a day after announcing it, even though its PD-1/VEGF bispecific ivonescimab headlined the ASCO plenary just two weeks ago. It seems that new stories with strong science are getting funded, but existing companies that haven’t delivered on past wins aren’t.

BIOTECH/PHARMA NEWS 🧬

🔹 AstraZeneca used the American Diabetes Association meeting to convert a licensed asset into a franchise commitment. In the Phase 2 VISTA obesity trial, elecoglipron at 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, with the curve still climbing to 11.8% at 36 weeks. In the SOLSTICE Type 2 diabetes trial, the same dose cut HbA1c by 1.9% from baseline versus 0.2% on placebo, with 90% of treated patients reaching HbA1c below 7%. No liver safety signals, infrequent discontinuations. The efficacy is roughly in line with, not ahead of, Lilly’s oral orforglipron, which is why some analysts called the pill “relatively underwhelming.” That reading misses the strategy. AstraZeneca is launching the EMBOLD trials in obesity and the ELUMINATE trials in diabetes, including cardiovascular and kidney outcomes studies and a combination with dapagliflozin. A small molecule oral GLP-1 that’s merely competitive on weight but pairs naturally with AstraZeneca’s existing cardio-renal portfolio is a different commercial proposition than a standalone weight loss drug. The obesity market now has four serious players: Lilly, Novo, Pfizer-Metsera, and AstraZeneca. And the fight is no longer about who can produce the biggest weight loss number. It’s about who can win on convenience, combination opportunities, and payer access.

🔹 A growing share of US employers are planning to drop GLP-1 coverage for weight loss in 2027, because too many employees are taking the drugs and the costs have become unsustainable. Real world persistence makes this worse: adherence falls from 65% at 120 days to 34% at one year. The efficacy race between Lilly’s retatrutide and Novo’s CagriSema is happening on top of a reimbursement system that’s starting to give way. The next phase of the market isn’t going to be about who loses the most weight. It’s about who can be taken long enough, and affordably enough, for the weight loss to actually matter.

🔹 Novartis booked two wins on its platform acquisition strategy in one week. First, the biomarker cohort of the FORTITUDE Phase 1/2 trial of del-brax in facioscapulohumeral muscular dystrophy met its primary and key secondary endpoints, with reductions in disease biomarkers indicating strong target engagement and reduced muscle damage. Del-brax is the asset that came through Novartis’s $12B Avidity acquisition that closed in February, and the result validates that price tag while a 200-patient Phase 3 enrolls across the US and Europe. The drug is an antisense oligonucleotide conjugate, extending the modality’s category-defining run into neuromuscular disease after recent wins in hereditary angioedema and metabolic disease. Second, Novartis extended its molecular glue partnership with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones to apply Orionis’s discovery platform to hard targets. Molecular glues are the cheaper, orally deliverable cousin of the degrader modality that crossed its regulatory threshold this spring with the Veppanu approval. Novartis is buying optionality across both validated and emerging modalities rather than building each in house.

🔹 Gilead and Merck delivered a win and miss this week. The win: the Phase 3 ISLEND-1 and ISLEND-2 trials of a once weekly oral islatravir + lenacapavir regimen met their primary efficacy endpoint with safety comparable to daily standard of care in virologically suppressed patients. This would be the first oral once weekly HIV treatment, a meaningful convenience step that protects Gilead’s core antiviral business against the long acting injectable threat. The miss: the EVOKE-03 trial of Trodelvy + Keytruda versus Keytruda alone in first line PD-L1-high non small cell lung cancer was stopped early, posting a numerical but not statistically significant progression free survival improvement. The miss carries read through beyond Gilead. It lands one week after Merck’s own TROP2 antibody drug conjugate sac-TMT hit in first line lung cancer in a China-only trial, raising the question of whether the TROP2-ADC + checkpoint combination actually works in lung cancer, or whether last week’s win reflects something specific about the comparator and the patient population.

🔹 Parabilis Medicines priced the largest venture-backed biotech IPO on record, selling 33.5M shares at $20 for $670M, beating Kailera’s $625M record set in April. The company, formerly FogPharma and founded by Gregory Verdine, develops helix-shaped peptide drugs called Helicons designed to hit previously undruggable proteins. About $150M will fund the lead asset zolucatetide, a beta-catenin inhibitor heading to Phase 3 in desmoid tumors in the first half of 2027. The IPO extends a 2026 streak of 12 biotech debuts raising more than $4.1B. The same day Parabilis priced, Summit Therapeutics pulled a $500M share sale it had announced just one day earlier, citing market conditions, even though its PD-1/VEGF bispecific ivonescimab headlined the ASCO plenary just two weeks ago. Investors will pay top dollar for fresh precommercial stories and balk at adding to positions that haven’t rewarded prior good news.

🔹 Sanofi halted its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring committee found the study unlikely to show sufficient efficacy. The trial enrolled patients refractory to standard of care. No safety signals were identified. The companion VITALIZE Phase 3 in patients treated with intravenous immunoglobulin will be evaluated separately, but the failure removes one path for a complement-targeting therapy Sanofi had viewed as a potential blockbuster. CIDP is the same indication argenx and others are pursuing, and the futility readout reinforces that mechanistic rationale in autoimmune neurology isn’t translating cleanly into efficacy in refractory patients.

🔹 Takeda’s oral TYK2 inhibitor zasocitinib beat Bristol Myers Squibb’s marketed Sotyktu head-to-head in plaque psoriasis, achieving statistical superiority on all primary and secondary endpoints. At 16 weeks, more than a third of zasocitinib patients achieved complete skin clearance, more than double the rate seen on Sotyktu. This is the second approved therapy zasocitinib has topped, following an earlier win against Amgen’s Otezla. Takeda paid roughly $4B for the asset through its Nimbus Therapeutics deal, and a head-to-head superiority claim against the only marketed oral TYK2 inhibitor is the strongest possible commercial setup. Takeda is targeting a 2026 FDA filing with launch expected in 2027. Sotyktu’s positioning as the premium oral psoriasis option is now directly threatened by a next-generation molecule with cleaner data, before zasocitinib has even reached the market.

🔹 Lilly presented the full TRIUMPH-1 dataset behind its May topline at the ADA meeting. At 80 weeks, retatrutide produced mean weight loss of 28.3% (about 70 pounds) at 12 mg and 25.9% (about 64 pounds) at 9 mg in obesity without diabetes. The triple agonist hitting glucagon, GLP-1, and GIP receptors also showed superior HbA1c and weight reductions versus placebo in the TRANSCEND-T2D-1 diabetes study, with added improvements in systolic blood pressure and lipids. The 28% efficacy ceiling retatrutide set is now reinforced with full peer-presented data, and it reframes every competitor. Novo’s CagriSema, at 23% over 84 weeks, sits a tier below, and Novo’s chief scientific officer publicly conceded the jury is still out on how CagriSema stacks up against the tri-agonist. The retatrutide program now spans diabetes, obesity, sleep apnea, MASH, and cardiometabolic outcomes, making it less a drug and more a metabolic platform.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Angus Liu/Fierce Pharma

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

ASCO 2026 was the meeting where Chinese oncology stopped being a sourcing story and became a science story. For the first time in the society’s 61 year history, a drug that originated in China took the plenary stage. Akeso’s ivonescimab, a bispecific antibody that targets both PD-1 and VEGF simultaneously, beat an active PD-1 inhibitor head to head in first line squamous lung cancer and cut the risk of death by 34%. The comparator wasn’t placebo or chemotherapy. It was an approved checkpoint inhibitor, which makes this a Chinese asset setting a new global standard, published in The Lancet the same day. Behind it came two more positive China-run Phase 3 oncology readouts the same week: Bristol Myers Squibb’s bispecific antibody-drug conjugate cutting progression risk by 71% in triple-negative breast cancer, and Innovent’s claudin-targeted conjugate hitting its endpoint in gastric cancer. The center of gravity in oncology drug origination has visibly shifted east.

Washington noticed. Days after ASCO ended, a bipartisan House bill moved to fold biotechnology into the Comprehensive Outbound Investment National Security Act, which would subject US investment in Chinese biotech to national security review. The bill follows the Pfizer-Metsera and BMS-Hengrui deals from the past two months, and the framing is that Chinese drug development progress is now a security exposure. If it passes, it would put friction on exactly the licensing channel that Lilly, Merck, AstraZeneca, and BMS have been using to buy discovery speed at a discount. The cheapest, fastest moving early stage oncology data in the world is increasingly Chinese, and the US is now trying to restrict the capital that brings it onshore. Any large cap company actively negotiating a China asset deal just picked up a new timing risk.

Revolution Medicines was the Western story of the week. Daraxonrasib confirmed a doubling of overall survival in previously treated metastatic pancreatic cancer at the ASCO plenary, 13.2 months versus 6.7 months on chemotherapy, hazard ratio 0.40. Pancreatic cancer is one of the indications that has resisted progress for a generation, and the result drew a standing ovation. The more interesting signal is commercial. Patients and oncologists are already pressing for access to a drug that hasn’t been approved yet, which is something most oncology programs never have to deal with.

Lilly kept buying modality breadth while pushing back on pricing pressure. An RNA exon-editing deal with Ascidian worth up to $1.9B, a Korean GLP-2 obesity asset from Hanmi, a five program option deal with China’s Haisco, an ultimatum to 340B hospitals on discount data sharing, and a billion dollar cut to planned German manufacturing in response to German pricing reform. And in immunology, Abivax posted the best Phase 3 ulcerative colitis efficacy of the cycle and the stock got crushed anyway, because the safety table had cancer cases in it. A reminder that efficacy doesn’t clear the gate on its own when a chronic, non-life-threatening disease meets an oncogenic signal.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 Akeso’s ivonescimab became the first China-originated oncology drug ever selected for the ASCO plenary, with Phase 3 HARMONi-6 data showing it reduced the risk of death by 34% in first line advanced squamous non-small cell lung cancer versus tislelizumab, an active PD-1 inhibitor. Median overall survival hit 27.9 months, a 4.2 month improvement after 21.4 months of follow-up. Ivonescimab is a bispecific antibody that targets PD-1 and VEGF at the same time, and the results were published in The Lancet simultaneously with the presentation. This is the first regimen to show a survival edge over a checkpoint inhibitor in first line squamous disease. The geographic caveat stands. HARMONi-6 enrolled entirely in China, and Summit Therapeutics holds the US and ex-China rights and still needs Western confirmatory trials to convince the FDA. But the mechanism question is settled in a way it wasn’t before. A PD-1/VEGF bispecific can outperform the checkpoint inhibitors that currently define standard of care.

🔹 Bristol Myers Squibb’s izalontamab brengitecan, the EGFR-by-HER3 bispecific antibody-drug conjugate the company paid $800M for in 2023, posted positive Phase 3 data in the China-based PANKU-Breast02 study in previously treated metastatic triple-negative breast cancer. The drug cut the risk of progression or death by 71% versus chemotherapy and produced a 51.7% response rate against 20.5% for chemo, hitting both progression-free and overall survival co-primary endpoints. This is the first bispecific antibody-drug conjugate to clear dual primary endpoints in this setting. The competitive read for the marketed TROP2 conjugates, Gilead’s Trodelvy and the recently approved Datroway from AstraZeneca and Daiichi Sankyo, is direct. They now face a dual-target conjugate with a more potent payload landing harder on response rate.

🔹 Representatives John Moolenaar and Debbie Dingell introduced a bipartisan House bill to add biotechnology to the Comprehensive Outbound Investment National Security Act, which would require national security review of US investment in Chinese biotech. The bill follows the Pfizer-Metsera and Bristol Myers-Hengrui deals from the past two months and frames Chinese drug development progress as a security exposure. The practical effect, if it passes, would be friction on exactly the licensing channel that Lilly, Merck, AstraZeneca, and Bristol Myers Squibb have been using to buy discovery speed at a discount. ASCO proved the science is real. Washington responded by trying to gate the money. Companies mid-negotiation on China assets now carry a regulatory timing risk that didn’t exist a quarter ago.

🔹 Revolution Medicines confirmed the pivotal Phase 3 RASolute 302 result at the ASCO plenary: median overall survival of 13.2 months on oral daraxonrasib versus 6.7 months on chemotherapy in previously treated metastatic pancreatic cancer, a hazard ratio of 0.40 with p less than 0.0001. Progression-free survival was 7.2 months versus 3.6. Daraxonrasib is a multi-selective RAS inhibitor dosed at 300 mg once daily, and the survival doubling in an indication where median survival has barely moved in decades drew a standing ovation from the audience. The more telling signal is commercial. STAT reported that patients and oncologists are already pressing for access to a drug that hasn’t been approved, and analyst conversations have shifted from whether daraxonrasib works to how far the franchise expands into earlier lines and first-line use. That is a quality of problem most oncology programs never reach.

🔹 Lilly had another busy week of M&A on multiple fronts. The headline deal was an RNA exon-editing collaboration with Ascidian Therapeutics worth up to $1.9B for genetic kidney diseases. Lilly also took most rights to Hanmi’s GLP-2 obesity candidate sonefpeglutide, optioned up to five programs from China’s Haisco, and extended its delivery technology pact with Camurus. The GLP-2 mechanism is a new metabolic lever distinct from the GLP-1/GIP axis that defines Zepbound, fitting the pattern of buying adjacency rather than more of the same. At the same time, Lilly issued a data sharing ultimatum to 340B hospitals, demanding proof they are not double dipping discounts or losing access to them, and cut its planned German manufacturing investment by at least $1B in response to German drug pricing reform. Boehringer Ingelheim made a similar cut on the same day. Lilly is spending freely on modality breadth while using its scale to push back hard on any policy that compresses net pricing.

🔹 Alnylam signed a three year AI deal worth up to $2B with Inceptive Nucleics, with $30M upfront in cash and equity, to build RNA foundation models. Inceptive was founded by Jakob Uszkoreit, one of the co-authors of the original transformer architecture paper that underpins modern large language models. The aim is to design and prioritize RNAi therapeutics computationally rather than empirically. The deal sits alongside NewLimit’s $435M round for epigenetic reprogramming, with Lilly Ventures participating, as evidence that AI and biology capital is now flowing to incumbents buying compute capability, not just to startups selling it. The small upfront, large milestone ceiling structure treats AI design as a high option, low commitment bet.

🔹 Abivax’s obefazimod, an oral miR-124 enhancer in ulcerative colitis, hit its Phase 3 ABTECT maintenance primary endpoint cleanly. The 25 mg and 50 mg doses produced clinical remission at Week 44 in 50.8% and 51.3% of patients respectively versus 10.4% on placebo, a roughly 40-point placebo-adjusted gap that is among the strongest ever reported in ulcerative colitis, with all key secondary endpoints met. The market sold the stock hard anyway, because the safety table reported cancer cases among treated patients, concentrated at the high dose. This is the immunology evidentiary bar in its purest form: efficacy alone doesn’t clear the gate when a chronic, non-life-threatening disease meets an oncogenic safety question. Abivax, a reported takeover target, plans an FDA filing in Q4 2026, and the label fight will be about dose and malignancy monitoring, not whether the drug works.

🔹 Celcuity presented full Phase 3 VIKTORIA-1 data showing its gedatolisib triplet extended median progression-free survival to 11.1 months versus 5.6 months for alpelisib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative advanced breast cancer, a 50% reduction in progression risk. The doublet matched it at 11.3 months. An investigator called it a potential new standard of care, and gedatolisib, a multi-target inhibitor of the PI3K/AKT/mTOR pathway, clearly beat the existing PI3K inhibitor on the market. The stock fell anyway, because expectations had been set at “transformative” and an 11-month median against an old comparator read as merely good. A useful reminder that in crowded breast cancer, the bar for a clean Phase 3 win is now set by investor narrative as much as by the curve.

🔹 Roche disclosed that giredestrant, its oral selective estrogen receptor degrader, missed in first-line metastatic breast cancer, and is redirecting the program into a new adjuvant Phase 3 rather than abandoning it. The result extends a difficult stretch for the oral SERD class, coming weeks after AstraZeneca’s camizestrant drew a 6-3 ODAC vote against its first-line switch strategy. The pattern is consistent: oral SERDs are struggling to prove first-line benefit against entrenched endocrine backbones, and the survivors are retreating to narrower biomarker-defined or earlier-stage settings where the comparator is weaker.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Angus Liu/Fierce Pharma

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

GSK and Ionis published Phase 3 data in the New England Journal of Medicine showing that bepirovirsen, an antisense oligonucleotide, functionally cured roughly one in five chronic hepatitis B patients across two trials totaling 1,838 patients. The standard of care for the past two decades has been indefinite antiviral therapy that suppresses the virus without ever clearing it. Twenty percent functional cure rates after 24 weeks of dosing is not a marginal improvement. Combined with Madrigal-Arrowhead’s PNPLA3 deal earlier this month and Intellia’s CRISPR Phase 3 win in hereditary angioedema, oligonucleotide modalities have now stacked three category-defining wins in five weeks across virology, metabolic disease, and rare disease.

Lilly’s $3.8 billion vaccine buying spree is the most strategically interesting move the company has made all year. The official framing was about preventing disease at the source rather than treating it later, which reads as polite cover for the real story. Lilly is using GLP-1 cash flow to build franchise breadth it has never had. Curevo’s Phase 2 shingles asset goes directly at GSK’s $4 billion Shingrix franchise. LimmaTech’s Phase 1 Staphylococcus aureus vaccine targets surgical site infections, an indication with no approved vaccine. Vaccine Co.’s preclinical Epstein-Barr virus candidate is a bet on multiple sclerosis prevention. This is Lilly’s tenth acquisition of 2026, and roughly half of those deals are in modalities Lilly does not currently run at scale: gene editing, non-viral delivery, vaccines, dual-payload ADCs. You can read the strategy in the deal flow: buy delivery and infrastructure now, deploy retatrutide cash on indication coverage later.

CVS Caremark reversed its 2025 Wegovy-only obesity formulary this week, adding Foundayo as a covered option starting June 1 and restoring Zepbound as a preferred option October 1, with Wegovy’s products remaining covered. Lilly now has obesity drug coverage across all three major pharmacy benefit managers. The bear case had been that Foundayo’s launch would lag because PBM access was structurally tilted toward Novo, and indeed Foundayo had been pacing at about 30% of oral Wegovy’s six week prescription trajectory. That handicap is now lifted. Lilly shares moved up about 6% on the news. The obesity fight is back to being about efficacy, convenience, and net pricing.

Daiichi Sankyo’s Datroway became the first TROP2 antibody-drug conjugate approved in first-line triple-negative breast cancer this week, with overall survival of 23.7 months versus 18.7 months on chemotherapy. That is the first time any targeted therapy has beaten chemotherapy on survival in this patient population. ADCs are now first line therapy in tumors that have been chemotherapy-only for decades, which is the same trajectory Enhertu took in HER2-positive breast cancer: second-line approval, then label expansion, then first line displacement.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 GSK and Ionis released full Phase 3 data on May 28 for bepirovirsen in chronic hepatitis B, alongside publication in the New England Journal of Medicine. In B-Well 1, 20% of patients on bepirovirsen plus antivirals achieved functional cure, defined as sustained loss of hepatitis B surface antigen with undetectable viral DNA, versus 0% on placebo plus antivirals. B-Well 2 showed 19%. Cure rates climbed to 25-28% in patients with lower baseline viral protein levels. Patients with undetectable disease at week 48 discontinued standard antiviral therapy. Bepirovirsen is an antisense oligonucleotide developed by Ionis and licensed to GSK. The FDA decision is due October 26. Chronic hepatitis B affects roughly 254M people globally, and the current standard of care, nucleoside analogs, suppresses the virus but rarely eliminates it. A 20% cure rate with a 24-week course is a category redefining number. The open question is pricing and access in the regions where the disease burden is heaviest (China, sub-Saharan Africa, and Southeast Asia).

🔹 Lilly announced three vaccine acquisitions on May 26 worth up to $3.83B in milestone-contingent value. Curevo (up to $1.5B) has a Phase 2 next-generation shingles vaccine using a synthetic adjuvant that has shown comparable immune response with fewer side effects than Shingrix. LimmaTech (up to $780M) has a Phase 1 Staphylococcus aureus vaccine for surgical site infection prevention. Vaccine Co. (up to $1.55B) is preclinical with an Epstein-Barr virus vaccine, which has growing scientific support as a multiple sclerosis prevention target. Upfront amounts were not disclosed. This is Lilly’s tenth M&A move of 2026 and brings 2026 deal spend above $5B across vaccines, gene editing, non-viral DNA delivery, and dual payload ADCs. The strategic frame is that Lilly is treating GLP-1 cash flow as a one-time opportunity to build modality and indication breadth before the next cycle.

🔹 CVS Caremark reversed its 2025 Wegovy-only obesity formulary on May 28, adding Foundayo (oral orforglipron) effective June 1 and restoring Zepbound as a preferred option October 1. Wegovy stays covered. Lilly’s obesity drugs now have coverage across all three major pharmacy benefit managers. The structural handicap on Foundayo’s launch, which had been running at about 30% of oral Wegovy’s early prescription pace, is now lifted. Lilly shares moved up about 6% on the announcement. The commercial competition resolves back to a head-to-head on efficacy, convenience, and net pricing, and Lilly’s retatrutide submissions later this year only widen the efficacy gap.

🔹 Verve Therapeutics, now owned by Lilly, presented Phase 1 data for VERVE-102 at the European Atherosclerosis Society Congress on May 26, with simultaneous publication in the New England Journal of Medicine. The trial enrolled 35 patients across six dose levels. LDL cholesterol reductions ranged from 9% to 62% across doses, with PCSK9 protein reductions of 55% to 88%. Durability of effect held for up to 18 months after a single infusion, the longest follow-up disclosed for any in vivo base editing therapy. No treatment-related adverse events. The top dose effect approaches what Amgen’s Repatha delivers as a chronic biologic that costs about $6k a year. Lilly plans to launch Phase 2 by the end of 2026. The regulatory question has shifted from whether the technology works to whether 18 month durability is sufficient to support a one time administration label rather than periodic redosing.

🔹 Apogee Therapeutics secured up to $1.3B in non-dilutive royalty financing from Blackstone Life Sciences to fund three Phase 3 trials of zumilokibart, an anti-IL-13 antibody, in atopic dermatitis. Phase 2 data showed 66% of mid-dose patients achieved 75% skin clearance versus 23% on placebo. The drug’s structural differentiator is dosing frequency: 2 to 4 injections per year versus every 2 to 4 weeks for Dupixent and Ebglyss. Trials begin in the second half of 2026. The fact that Blackstone is willing to underwrite three Phase 3 trials non-dilutively says something about how the eczema biologic market is now structurally bid for differentiated dosing rather than just efficacy.

🔹 Daiichi Sankyo and AstraZeneca’s Datroway received FDA approval on May 22 in first line metastatic triple negative breast cancer for patients ineligible for checkpoint inhibitor therapy. The Phase 3 trial showed median overall survival of 23.7 months versus 18.7 months on chemotherapy, a hazard ratio of 0.79. This is the first TROP2 antibody-drug conjugate approved in first-line triple-negative breast cancer and the first targeted therapy to show an overall survival benefit over chemotherapy in this population. Datroway now competes against Gilead’s Trodelvy and pushes ADC platforms further into first-line settings that have been chemotherapy-only for decades.

🔹 Biogen and Denali announced that BIIB122, an LRRK2 inhibitor, missed its primary endpoint in the Phase 2b LUMA trial in idiopathic Parkinson’s disease. The partners are ending development in that population. The trial tested whether LRRK2 inhibition slowed motor and clinical progression in idiopathic patients regardless of LRRK2 mutation status, and the answer was clearly no. The parallel LIGHTHOUSE trial in LRRK2 mutation-positive patients continues. For Denali, the commercial story remains AVLAYAH, their brain-penetrant Hunter syndrome therapy launched in April. For Biogen, this is the second neurology Phase 2b miss in twelve months and reinforces a pattern of large cap neurology platforms failing on symptom-progression endpoints despite biomarker rationale.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Image source: Getty Images

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

Treating a new realm of diseases

Beyond traditional limits: explore the drug delivery technology opening new doors in genomic medicine.

Watch episode

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

The number that defines this week is 28.3%. That is the average body weight lost on the 12 mg dose of Lilly’s retatrutide in TRIUMPH-1, the first successful Phase 3 readout for the GIP/GLP-1/glucagon triple agonist that has been the most watched obesity asset in the pipeline for two years. A second pivotal trial in patients with knee osteoarthritis hit 28.7% plus a 75.8% reduction in pain scores. We have officially entered the territory where a pill or injection produces weight loss comparable to bariatric surgery. The bear case on incretin pricing pressure may eventually arrive, but the front of the efficacy curve just moved again, and Novo Nordisk’s CagriSema and Pfizer’s Metsera assets now have to be measured against a 30% ceiling rather than a 25% one. The wrinkle worth holding onto is the discontinuation curve. 11.3% of patients on the 12 mg dose dropped out for adverse events versus 4.9% on placebo, which is why the 9 mg arm is probably the commercial sweet spot.

The other big story this week is about how pharma is choosing to build, not what it is building. The same Lilly that posted the retatrutide data also acquired Engage Bio for up to $202 million, its seventh M&A move of 2026, to pick up a non-viral DNA delivery platform. Bristol Myers Squibb signed a strategic agreement with Anthropic to deploy Claude across more than 30,000 employees in a workflow-embedded configuration that goes well beyond a chatbot. Incyte struck two AI deals the same week. The emerging pattern is that large pharma is buying discovery infrastructure now, and enterprise AI has crossed from “nice to have” into table stakes.

Two weeks after Marty Makary’s exit, the FDA story has moved from leadership churn into something more operational. Endpoints published an investigation into the coordinated campaign of biotech executives, lobbyists, and former FDA officials that pushed him out, with Biohaven CEO Vlad Coric as a central figure after his company’s pushback on a late-April complete response letter. On the same day, the acting head of NIAID reportedly stepped down, and NIH Director Jay Bhattacharya was grilled by Senate Appropriations on the 2027 budget. The leadership vacuum is widening, not narrowing. If you have a PDUFA date or a Type B meeting on the calendar this summer, you should probably plan for delays.

Outside obesity and US policy, the most strategically important readout came out of China. Merck partner Kelun-Biotech’s sac-TMT combined with Keytruda cut the risk of tumor progression or death by 65% versus Keytruda alone in first-line PD-L1-positive non-small cell lung cancer. This is the first Phase 3 trial of an antibody-drug conjugate combined with a checkpoint inhibitor to win in first line lung cancer. Keytruda loses patent exclusivity in 2028, and Merck’s strategic response is to convert it into a backbone for combination regimens. Nobody really cares anymore that the asset came from China. The next real test is whether the Western confirmatory study running in parallel reproduces the result.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 Lilly reported positive Phase 3 topline results for retatrutide, its triple-agonist obesity drug, in adults with obesity or overweight plus at least one weight-related comorbidity without diabetes. After 80 weeks, the 12 mg dose drove 28.3% weight loss, roughly 70 pounds on average, versus 2.2% on placebo. The 9 mg dose delivered about 24% and the 4 mg dose about 19%. Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% across the three doses versus 4.9% on placebo, with nausea, diarrhea, and vomiting as the dominant side effects. A second trial in patients with obesity and knee osteoarthritis hit 28.7% weight loss and a 75.8% reduction in WOMAC pain scores at the high dose. Seven additional retatrutide Phase 3 trials read out through 2026 across diabetes, sleep apnea, MASH, chronic low back pain, and cardiovascular outcomes. Lilly is no longer fighting on the same efficacy frontier as Novo’s CagriSema, which posted 22.7% in a comparable population last year. The likely commercial read is that retatrutide expands the obesity market rather than cannibalizing Zepbound, because the 12 mg discontinuation rate creates real-world dose ceiling effects. Lilly will not run pricing off the 12 mg label.

🔹 Lilly also closed its acquisition of Engage Bio for up to $202M, picking up a non-viral DNA delivery platform that combines engineered DNA payloads with lipid nanoparticles. The aim is to solve the persistent problems with gene therapy delivery: potency, tolerability, and the ability to redose, all of which have constrained the AAV-based approaches Sarepta and others have relied on. This is Lilly’s seventh acquisition of 2026 and continues a clear strategic pattern: the company is treating genetic medicine as a delivery problem rather than a payload problem.

🔹 Endpoints News published an investigation this week describing a multi-month coordinated effort by biotech executives, lobbyists, and former FDA officials that contributed to Marty Makary’s departure on May 12, with Biohaven CEO Vlad Coric featured prominently after Biohaven’s late-April complete response letter on a spinocerebellar ataxia program. The broader regulatory landscape is also fraying. The acting head of NIAID reportedly stepped down, and NIH Director Jay Bhattacharya faced bipartisan Senate scrutiny on the 2027 budget. The practical implications include real delay risk for PDUFA decisions, Type B meeting outcomes, and advisory committee scheduling for at least the rest of the quarter, with small-cap companies under $200 million in cash and active regulatory engagement the most exposed.

🔹 Kelun-Biotech released the OptiTROP-Lung05 Phase 3 abstract ahead of ASCO 2026, reporting a 65% reduction in the risk of tumor progression or death for sac-TMT combined with Keytruda versus Keytruda alone in previously untreated PD-L1-positive non-small cell lung cancer. Sac-TMT is a TROP2-directed antibody-drug conjugate carrying a topoisomerase I inhibitor payload, and Merck licensed ex-China rights from Kelun back in 2022. This is the first Phase 3 of any antibody-drug conjugate plus checkpoint inhibitor combination to hit in first line lung cancer. The competitive read matters as AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan has struggled to convert Phase 3 signals into a first line label, and Merck now has a credible path to turn Keytruda into a combination backbone heading into its 2028 patent expiration. The enrollment was China-only, and Western confirmatory trials are running in parallel, so the question of whether the regional efficacy translates is real. The 65% magnitude is large enough that even a substantial regional discount would still be commercially material.

🔹 BMS signed a strategic agreement with Anthropic to deploy Claude across more than 30k employees globally, with use cases spanning scientific literature summarization, clinical protocol drafting, internal data querying, and routine documentation. The deal also includes Claude Code for research and drug development functions. Combined with Incyte’s two AI deals the same week, it seems that enterprise AI is now baseline infrastructure for top-20 pharma rather than a differentiated capability.

🔹 Immunovant reported Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, with ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in patients who had failed at least two prior advanced therapies, including both JAK and anti-TNF inhibitors. Response rates held in the subgroup that had failed both classes. Shares moved on the print. The proof-of-concept readout in cutaneous lupus is expected in the second half of 2026 and will be the next decisive print for the company’s autoimmune blockbuster thesis.

🔹 BioMarin’s Voxzogo hit the primary endpoint in a Phase 3 trial in hypochondroplasia, with annualized growth velocity 2.33 cm per year above placebo at Week 52, opening a second pediatric short-stature indication beyond the original achondroplasia label. Filings are planned for the second half of 2026. Two days earlier, BMN 401, an enzyme therapy acquired in the 2025 Inozyme buyout, missed its radiographic clinical endpoint in ENPP1 deficiency despite hitting on the biomarker co-primary, and will require FDA discussion on surrogate to clinical translation.

Share

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

You can listen to this episode on YouTube, Spotify or Apple Podcasts.

In the latest joint podcast episode by Biotech Blueprint × Biotech Capital Compass, we zoom in on Moderna and where the company stands in 2026. We work through the Q1 earnings beat, the unprecedented FDA refusal-to-file on mRNA-1010, the CMV Phase 3 failure, the Vertex cystic fibrosis wind down, and the individualized neoantigen therapy (INT) program that has moved to the center of the pipeline. The short companion piece below picks up one thread from the conversation, which is the pattern across Moderna’s wins and losses, and what it suggests about where the platform actually works.

Share

Here’s a link to our previous mRNA podcast episodes:

The successes are all acute. COVID-19, RSV via mRESVIA, the seasonal flu candidate, INT. Each one needs a burst of antigen or a pulse of immune training, and then the body takes it from there. The disappointments are the opposite. CMV is a latent virus that hides intracellularly for life and needs durable, often mucosal immunity to keep suppressed. The Vertex-partnered inhaled mRNA program for CF patients without CFTR protein required continuous replacement of a protein the body cannot make on its own. Both programs were asking the platform to do something it isn’t really built to do.

The biology is straightforward. An mRNA-LNP delivers its cargo into a cell, the ribosomes translate it for a day or two, cytosolic nucleases degrade the mRNA, the LNP clears, and detectable protein is gone within a week or two. Modified nucleosides like N1-methylpseudouridine stretch the translation window a bit and dampen innate sensing, but they do not change the fundamental kinetics. mRNA is, by design, a short-burst technology. That is exactly what you want for a vaccine. It is much harder to make it the right tool for sustained protein replacement, or for the kind of tissue-resident memory T cell response you would want against a virus that is going to live in your body forever.

Hartaj framed the underlying question on the episode this way:

“…One of the things that Moderna is having to go through right now is figure out where is it really that the mRNA modality can work.”

— Hartaj Singh (Biotech Capital Compass)

One way to read the last year of Moderna news is that the platform has been answering that question for them. The successes mark out the shape of what it does well and the failures mark out where it doesn’t. The strategic pivot toward oncology and acute respiratory, and away from latent viruses and chronic protein replacement, looks less like a retreat under cash pressure and more like the company drawing the right roadmap.

That makes INT (mRNA-4157) the cleanest test of where this goes. Each product codes for up to 34 patient-specific neoantigens, selected from tumor sequencing by predicting which mutated peptides will bind that patient’s HLA molecules and present on the tumor surface where cytotoxic T cells can find them. Melanoma is the natural first indication because it carries one of the highest tumor mutational burdens of any solid tumor, which gives the selection pipeline more candidates to choose from. Non-small cell lung cancer extends the test to a much larger patient population. INT plays to what mRNA is good at. A focused immune-training event, then the patient’s T cells do the work. If the melanoma signal holds in NSCLC, the read above is probably right. If it doesn’t, mRNA’s reach is narrower than even this piece is suggesting.

Everything else from the episode is near-term noise. The Q1 earnings beat was helpful but ambiguous, since Q1 is seasonally weak and expectations had been cut. The August 5 PDUFA decision on mRNA-1010 will tell us more about whether the regulatory environment is functionally hostile to mRNA respiratory vaccines under this administration than it will about the trial itself.

One quick teaser for next time. The thread we deliberately did not pull on this week is the role of machine learning in INT. The FDA has indicated it wants the neoantigen selection algorithm submitted as part of the regulatory package, which is the first time we are aware of an AI/ML system being treated as a regulated component of a therapy rather than as a tool sitting upstream of it. That is a bigger story than it sounds, and it gets its own episode.

Three Takeaways

1. Moderna’s successes and failures cluster along one axis. Acute, episodic, pulse-style indications on one side. Sustained, latent, chronic indications on the other.

2. The strategic pivot reads more cleanly as realignment. The company is moving toward indications where the biology fits.

3. INT is the test. The 2026 readouts will tell us whether the platform is broadly useful in oncology, or whether even oncology turns out to be narrower than we hope.

Listen to the full episode on YouTube, Spotify, or Apple Podcasts. Our next episode picks up the thread on AI, machine learning, and what it means when the algorithm itself becomes part of the drug.

Thanks for reading Biotech Blueprint!

Share

Subscribe now

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Photo credit: Moderna

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

Three large stories defined the week. Bristol Myers Squibb committed up to $15.2B to license 13 early stage assets from China's Hengrui Pharma, betting that external discovery at Chinese R&D speed is the fastest path to pipeline. On the same day, FDA Commissioner Marty Makary resigned after weeks of pressure, adding a new layer of regulatory unpredictability to an already unstable agency. And on Thursday, Regenxbio posted a clean Phase 3 win in Duchenne muscular dystrophy, landing in the middle of Sarepta’s ongoing Elevidys safety crisis.

The BMS-Hengrui deal is really about the China R&D speed differential. BMS executives explicitly cited that clinical trial filing timelines in China run 50-70% faster than the rest of the world, and they structured the deal accordingly. $600M upfront, another $350M in fixed payments over 30 months, four Hengrui oncology and hematology assets ex-China, four BMS immunology assets going the other direction, and five jointly discovered programs. The specific molecular targets weren’t disclosed. Chinese discovery engines are now treated as outsourceable infrastructure by large pharma, not competitive risk. Pfizer’s Kailera deal, Merck’s Terns acquisition, and now this are all expressions of the same logic.

Makary’s resignation is the story with the most immediate practical consequences for drug developers. His tenure produced unpredictable rejections, including Replimune’s second FDA rejection in late April that cost the company 60% of its workforce, high profile leadership departures including CDER director George Tidmarsh and oncology chief Richard Pazdur, who joined and left within three weeks, and sustained public industry frustration. Acting commissioner Kyle Diamantas comes from the food side of the FDA with no drug review track record. For companies midway through regulatory review, the risk is silence because Type B meetings might stall through summer while a permanent successor is found.

Regenxbio’s RGX-202 result is the cleanest dataset of the week. In 30 boys with Duchenne muscular dystrophy, a single dose of the gene therapy drove mean microdystrophin expression of 71.1%, with 93% of patients crossing the 10% threshold that served as the primary endpoint. More importantly, the trial formally bridged biomarker to function: microdystrophin expression at week 12 was statistically significantly correlated with functional improvement at one year on a standardized motor assessment. That biomarker-to-function link is what prior Duchenne gene therapy submissions have been missing, and it's what gives this dataset a credible accelerated approval path rather than just scientific interest. Sarepta’s Elevidys currently carries a boxed warning for liver injury after three patient deaths and lost its platform technology designation. RGX-202 gives prescribers a real second option for the first time.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 Bristol Myers Squibb announced a global strategic collaboration with Hengrui Pharma on May 12 covering 13 early stage programs across oncology, hematology, and immunology. BMS pays $600M upfront, $175M on the first anniversary, and a contingent $175M in 2028, with total deal value reaching $15.2B if all milestones are hit. BMS gets exclusive ex-China rights to four Hengrui oncology and hematology assets. Hengrui gets four BMS immunology assets inside Greater China, and five programs will be jointly discovered with Hengrui leading early clinical work. Specific targets were not disclosed. The deal closes Q3 2026 pending antitrust clearance. This is the largest single pharma-China licensing deal of 2026 and the clearest signal yet that big pharma has stopped treating Chinese R&D as a competitive threat and started treating it as a supply chain.

🔹 FDA Commissioner Marty Makary resigned on May 12, with Deputy Commissioner for Food Kyle Diamantas named acting head. The immediate trigger was reportedly a dispute with the White House over fruit-flavored vape approvals, but the structural pressure had been building for months: CDER director George Tidmarsh departed, Richard Pazdur joined CDER and left within three weeks, and a string of high profile rejections including Replimune’s second complete response letter generated sustained industry pushback. The Biotechnology Innovation Organization issued a same day statement calling for organizational stability. Diamantas has no drug review background, and a permanent successor has not been named. For companies in active regulatory review, the near term risk is delays in Type B meeting feedback and PDUFA decisions while the commissioner's office transitions. Industry executives have reportedly floated Pazdur as a permanent replacement, though his recent departure complicates that path.

🔹 REGENXBIO reported positive pivotal Phase 3 data for RGX-202, an AAV8-delivered microdystrophin gene therapy for Duchenne muscular dystrophy, on May 14. In 30 ambulatory boys, 93% achieved microdystrophin expression above 10% at week 12, with mean expression of 71.1% across the full cohort. The headline number that matters most for the regulatory path: microdystrophin expression at week 12 was statistically significantly correlated with functional improvement on the North Star Ambulatory Assessment at one year, the first time a Duchenne gene therapy has formally bridged biomarker to function in a registration dataset. Two serious adverse events were reported, a case of subacute myocarditis that resolved and an asymptomatic liver enzyme elevation that normalized. REGENXBIO is pursuing accelerated approval with a 2027 commercial launch target. Sarepta’s Elevidys carries a boxed warning for serious liver injury after three patient deaths and is approved only for ambulatory patients aged 4 and older. RGX-202’s safety profile to date is the commercial differentiator.

🔹 Isomorphic Labs, the Alphabet-backed DeepMind spinout focused on AI drug design, closed a $2.1B Series B on May 12 led by Thrive Capital, with participation from Alphabet, GV, Temasek, and both the UK Sovereign AI Fund and Abu Dhabi’s MGX. This is the largest AI biotech private round on record. The capital funds continued development of the company’s AI drug design engine and its own therapeutic pipeline, with first-in-human trials targeted for late 2026. Isomorphic retains active partnerships with Novartis, Lilly, and J&J. This is no longer a company positioning itself as a service layer for pharma. It’s funded to be an integrated drug discoverer and developer. Whether AI-designed molecules clear Phase 1 this year is the credibility test for the entire category.

🔹 argenx received FDA approval on May 8 expanding Vyvgart and Vyvgart Hytrulo to all adult patients with generalized myasthenia gravis, including antibody negative patients who previously had no on label biologic options. The Phase 3 ADAPT SERON trial in 119 antibody-negative patients hit its primary endpoint with p=0.0068. argenx reported Q1 product net sales of $1.3B, up 63% year-over-year, its seventeenth consecutive quarter of growth. The label expansion removes the antibody status gating step that had been slowing prescribing decisions in community neurology. Vyvgart is now the only treatment approved for the full generalized myasthenia gravis patient population.

🔹 Italy’s Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, roughly $4.1B and a 28% premium, giving Angelini its first US foothold through Catalyst’s rare neurology portfolio: FIRDAPSE, the only FDA-approved treatment for Lambert-Eaton myasthenic syndrome, AGAMREE, an alternative steroid for Duchenne, and US rights to FYCOMPA for partial-onset seizures. This is the second European mid cap pharma company to buy a US-marketed rare neurology asset in as many weeks, after Chiesi’s KalVista deal, and the pattern likely reflects urgency to build US-marketed inventory ahead of Section 232 pharma tariffs taking effect July 31.

Share

WATCHLIST 👀

• ASCO 2026 Plenary, May 31: Daraxonrasib LBA5 from Revolution Medicines (Phase 3 RASolute 302, 2L metastatic PDAC, OS 13.2m vs 6.7m, HR 0.40). Final analysis and additional subgroup detail. Plenary slot is the highest-profile oncology platform of 2026.

• FDA permanent commissioner nomination: Trump has named Diamantas only as acting. Pazdur was floated by industry but already departed. Watch for nomination signals from HHS and Senate HELP Committee

• REGENXBIO BLA submission for RGX-202: Accelerated approval pathway flagged. FDA surrogate endpoint discussion is the gating step. Likely Q3 2026 filing.

• EHA 2026 Congress, Stockholm, June 11-14: First clinical data from Ajax Therapeutics’s AJ1-11095 (Type II JAK2 inhibitor for myelofibrosis), the asset Lilly is acquiring for up to $2.3B (closing expected H2 2026)

• Cytokinetics aficamten NDA filing timeline: Investor day or topline regulatory commentary at HFSA expected; ACACIA-HCM full data presentation at upcoming cardiology meeting.

• BMS-Hengrui assets disclosed at closing: Specific molecular targets, modality breakdown, and any GLP-1 or ADC programs included in the 13 asset portfolio

• Q2 2026 earnings season, late July-early August: First quarter under MFN drug pricing implementation; first commentary on Section 232 pharma tariff impact (effective July 31)

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: Anna Moneymaker/Getty Images

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

The biggest story this week is a modality. The FDA approved Veppanu on May 1, the first PROTAC protein degrader ever cleared by the agency, in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The Phase 3 numbers are modest: median progression-free survival of 5 months versus 2.1 months on fulvestrant in the ESR1-mutated subgroup, and the broader trial population missed statistical significance entirely, which is why the label is restricted to patients with a confirmed ESR1 mutation identified by a companion diagnostic blood test. None of that matters as much as the fact that targeted protein degradation now has a regulatory template. PROTACs work by recruiting cellular machinery to destroy a disease-causing protein entirely rather than just blocking it, and the field has been waiting years for proof that the FDA would accept this pharmacology at the registration level.

The second theme running through the week is precision medicine moving into common diseases. Two siRNA deals landed within 48 hours. Madrigal paid Arrowhead $25M upfront and up to $975M in milestones for an siRNA targeting a single genetic variant, the PNPLA3 I148M mutation, that drives MASH progression in about 30% of patients with moderate to advanced fibrosis. The Phase 1 data showed 46% liver fat reduction in patients carrying two copies of the variant and zero effect in those carrying one, which is about as clean a genetic signal as you will see in a complex metabolic disease. GSK followed the next day with a $1B deal for SiranBio’s ALK7-targeting siRNA, designed to reduce visceral fat while preserving lean mass, a profile that could complement GLP-1s rather than compete with them. Both are siRNA, both treat conditions historically owned by small molecules, and both are explicit bets that genetically defined patient subgroups are worth pursuing even when the overall population is large.

Obesity is now an earnings story. Novo Nordisk reported oral Wegovy pulling in roughly $355M in its first full quarter on the market, about double consensus, on 1.3M prescriptions. Total Q1 sales were up 32% on a constant currency basis. None of the bear cases on GLP-1 pricing pressure are showing up in actual results.

Cytokinetics had an important week. Aficamten hit both primary endpoints in non-obstructive hypertrophic cardiomyopathy, a form of the disease where there is currently no approved disease-modifying therapy and where BMS’s Camzyos has repeatedly failed. The placebo-adjusted efficacy improvements are modest on paper, but the trial swept the secondary endpoints too, and the indication is wide open. A safety flag around cardiac function will mean echo monitoring in any approved label, but that's routine in cardiology.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 The FDA approved Arvinas’ Veppanu (vepdegestrant) on May 1, eight months ahead of its scheduled review date, for adults with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after at least one prior line of endocrine therapy. In the Phase 3 VERITAC-2 trial, median progression-free survival was 5 months on vepdegestrant versus 2.1 months on fulvestrant in the ESR1-mutated subgroup, a 43% reduction in progression or death risk. The broader trial population missed statistical significance, confining the label to ESR1-mutated patients identified by the Guardant360 companion diagnostic blood test. Arvinas and Pfizer are not launching directly and are seeking a third-party commercialization partner, an unusual setup that likely reflects the narrow, biomarker-gated patient population. This is the first PROTAC heterobifunctional protein degrader ever approved anywhere, and it gives every other degrader program in development a regulatory roadmap.

🔹 Cytokinetics reported that aficamten hit both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy. Quality of life score improved 11.4 points versus 8.4 on placebo, and peak oxygen uptake improved 0.64 mL/kg/min versus a 0.03 decline on placebo. Secondary endpoints including functional class improvement and a key cardiac stress marker all hit with p less than 0.001. The safety flag: 10% of aficamten patients dropped their left ventricular ejection fraction below 50% versus 1% on placebo, with two serious heart failure events linked to that drop. Echo monitoring will be in any label. Cytokinetics has not given a regulatory submission date but says it will discuss findings with the FDA shortly.

🔹 Entrada Therapeutics reported early Phase 1/2 data for ENTR-601-44 in Duchenne muscular dystrophy patients with exon-44 amenable mutations. The 6 mg/kg cohort showed a mean dystrophin increase of 2.36% from a 4.00% baseline and a statistically significant improvement on a timed Rise from floor test, with no serious adverse events. Drug exposure in younger patients came in below adult levels, so the next cohort is now dosing at 12 mg/kg with more data expected by year end. The numbers are small and early, but a functional signal on top of a biomarker signal in a disease with very few options is enough to keep watching.

🔹 Madrigal licensed ARO-PNPLA3 from Arrowhead for $25M upfront and up to $975M in milestones, adding a precision siRNA alongside Rezdiffra, the only approved MASH drug. ARO-PNPLA3 targets the PNPLA3 I148M variant that drives liver fat accumulation in MASH, showing 46% liver fat reduction in patients carrying two copies of the variant and essentially no effect in those carrying one. Roughly 30% of MASH patients with moderate to advanced fibrosis carry two copies. The asset was originally co-developed with J&J before being deprioritized in 2023. Madrigal plans a Phase 2 combination trial with Rezdiffra, which starts to build a precision medicine MASH platform rather than a single asset story.

🔹 GSK agreed to pay up to $1B in milestones to license SA030, an siRNA targeting ALK7, from China-based SiranBio. ALK7 inhibition is designed to reduce visceral abdominal fat while preserving lean muscle mass, addressing one of the meaningful criticisms of GLP-1s, significant lean mass loss alongside fat loss. SiranBio retains China rights and runs the Phase 1 and GSK takes everything else. Two China-sourced siRNA assets in big pharma’s hands in 48 hours signals the modality is now platform and mature enough that large companies are licensing in rather than building from scratch.

🔹 Novo Nordisk reported first quarter sales of roughly $15.2B, up 32% on a constant currency basis, with oral Wegovy pulling in approximately $355M in its first full quarter, about double analyst consensus on roughly 1.3M prescriptions. Full year guidance was narrowed upward. Novo’s first mover advantage in the oral GLP-1 format is showing up in the numbers despite Lilly’s Foundayo entering the market in April.

🔹 Pfizer reported Q1 revenue of $14.45B, up 5% year over year, with Eliquis growing 13% to $2.17B and Comirnaty falling 59% to $232M. Full year guidance was reaffirmed. With the Metsera acquisition closed at roughly $7 billion enterprise value, Pfizer now owns MET-097i, a weekly and monthly injectable GLP-1 heading into Phase 3, plus a monthly amylin and an oral GLP-1 in Phase 1. The Lilly/Novo duopoly formally has a third serious contender.

🔹 Seaport Therapeutics and Hemab Therapeutics both priced upsized IPOs at $18, the top of their ranges, raising a combined $556M. April was the strongest biotech IPO month in five years. Institutional appetite for late stage biotech is back, but only for programs with clean data and a credible near term catalyst.

🔹 Q1 earnings data points. Vertex reported $2.99B in Q1 revenue with Casgevy at $43M and new pain drug Journavx at $29M on over 350k prescriptions in its first quarter. Bristol Myers Squibb reported Camzyos approaching 25k US patients. Regeneron reported Dupixent global sales of $4.9B, up 33%, while the overall Eylea franchise declined 10% as the newer HD formulation cannibalizes the original.

Share

WATCHLIST 👀

• Revolution Medicines: ASCO plenary LBA5 (daraxonrasib in 2L PDAC) on May 31, the dominant near-term oncology catalyst. Merck-Revolution acquisition talks reportedly broke down on price in late January at the $28B-$32B level

• IDEAYA Biosciences: ASCO LBA on darovasertib + crizotinib in HLA-A*02:01-negative uveal melanoma; NDA filing H2 2026

• Aficamten: Cytokinetics regulatory path discussion with FDA following ACACIA-HCM positive readout. Market expects label-expansion path with echo monitoring

• Veppanu launch: Arvinas-Pfizer third party commercialization partner selection; Q1 prescription metrics will set the bar for PROTAC class commercialization

• MET-097i (Pfizer-Metsera): VESPER-5 Phase 3 obesity readouts beginning across 10 pivotal studies in 2026

• Foundayo (Lilly orforglipron): Q2 prescription run rate, the Q2 test of oral GLP-1 demand against Wegovy oral

• Travere Therapeutics: Sparsentan FSGS PDUFA outcome (April 28, 2026) still not visibly resolved. Flagged as unverified for second consecutive week

• Intellia lonvo-z: Full HAELO Phase 3 safety table at upcoming conference. Rolling BLA submission progress

• United Therapeutics: Ralinepag NDA targeted H2 2026 (PAH). Tyvaso IPF regulatory path post-TETON-1

• Seaport (SPTX), Hemab: First-week trading prints will signal whether the IPO window stays open or tightens

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: https://dmpkservice.wuxiapptec.com/articles/5-an-overview-of-protac-technology-and-dmpk-research-strategy/ Example of PROTAC structure.

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

This week’s defining clinical event came on April 27, when Intellia Therapeutics reported that a single dose of lonvoctocogene-z, an in vivo CRISPR therapy, reduced hereditary angioedema attack rate by 87% versus placebo in Phase 3, with 62% of recipients attack-free or off other prophylactic therapy compared to 11% on placebo. This is the first Phase 3 win for any in vivo CRISPR therapy, and it matters because in vivo gene editing has faced persistent questions about whether it could deliver durable, tolerable results in a chronic non-cancer indication at the registration level. This trial answered that. Rolling regulatory submission has started, with a US launch targeted for the first half of 2027.

Two days later, Italy’s Chiesi agreed to acquire KalVista Pharmaceuticals for $1.9 billion for Ekterly, an oral on-demand hereditary angioedema rescue therapy barely nine months into commercial launch. Ekterly is rescue treatment. Lonvoctocogene-z is one shot prophylaxis. They serve different moments in disease management, but the long run question is whether a patient population that can functionally eliminate attacks with a single CRISPR dose will keep reaching for a rescue pill at the same rate. Chiesi paid a rare disease premium two days after the prophylaxis ceiling moved. Whether that was disciplined portfolio building or a misjudgment of modality risk, the market will render a verdict over the next few years.

The week’s M&A story was Sun Pharma’s $11.75 billion acquisition of Organon, the largest biopharma deal of 2026. Organon was spun out of Merck in 2021 with established brands and biosimilars, and Sun is buying scale in mature markets and manufacturing depth. The deal signals that Indian generics and emerging market specialty pharma are now serious players in large cap consolidation, and Section 232 tariff dynamics that disadvantage import-dependent biosimilar manufacturers may have added urgency to building US-domiciled scale.

On the regulatory side, the FDA’s advisory committee voted 6 to 3 against the clinical benefit of AstraZeneca’s camizestrant in a circulating tumor DNA-triggered first-line breast cancer switch setting, the agency’s first such meeting in nine months. The progression-free survival data was strong, a hazard ratio of roughly 0.44. The committee said no anyway, citing immature overall survival, confounded secondary endpoints, and a safety profile that’s hard to justify in a clinically stable population. The precedent is important: a compelling progression-free survival signal triggered by a liquid biopsy biomarker alone is not sufficient to move stable patients to a new therapy.

Earnings closed the week with Lilly posting $19.8 billion in first quarter revenue, up 56% year-over-year, with Mounjaro and Zepbound combining for $12.76 billion. Guidance was raised to $82 to $85 billion for the full year. Foundayo’s early launch data was mixed. 3,707 prescriptions in week two versus roughly 18k for oral Wegovy at the same stage, though Lilly noted 20k patients already on the drug by the earnings call. Volume growth across the franchise is more than offsetting pricing concessions, and the obesity narrative remains intact heading into ASCO season.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 Intellia Therapeutics reported that a single dose of lonvoctocogene-z, an in vivo CRISPR therapy, reduced hereditary angioedema attack rate by 87% versus placebo in Phase 3, with 62% of recipients attack-free or off other prophylactic therapy compared to 11% on placebo. Safety was clean, with no serious treatment-related adverse events in the topline. This is the first Phase 3 win for any in vivo CRISPR therapy, and it matters because in vivo gene editing, where the editing happens inside the body rather than in a lab dish, has faced persistent questions about whether it could deliver durable, tolerable results in a chronic non-cancer indication at the registration level. This trial, with a proper placebo control and a clean safety readout, is the clearest answer yet. Rolling regulatory submission has started, with a US launch targeted for the first half of 2027.

🔹 Italy’s Chiesi agreed to acquire KalVista Pharmaceuticals for $27 per share in cash, roughly $1.9B and a 36% premium to KalVista’s 30 day average price. KalVista’s only marketed asset is Ekterly, an oral on-demand plasma kallikrein inhibitor approved in July 2025 for hereditary angioedema attacks, barely nine months into commercial launch. The timing is uncomfortable. Ekterly is rescue therapy. Lonvoctocogene-z is one shot prophylaxis. They serve different moments in disease management, but if patients can functionally eliminate attacks with a single CRISPR dose, the lon run volume outlook for rescue therapy gets harder to underwrite. Chiesi paid the rare disease premium two days after the prophylaxis ceiling moved. That timing will be debated for a while.

🔹 The FDA’s Oncologic Drugs Advisory Committee voted 6 to 3 on April 30 against the clinical benefit of AstraZeneca’s camizestrant in a specific first-line breast cancer setting, the agency’s first such meeting in 9 months. The SERENA-6 trial randomized patients who developed an ESR1 mutation during first-line hormone therapy plus a CDK4/6 inhibitor to either switch to camizestrant or stay on their current regimen. Progression free survival was 16.0 to 16.6 months on camizestrant versus 9.2 months on continued therapy, a hazard ratio of roughly 0.44, which is a large effect. The committee wasn’t convinced: secondary endpoints were confounded by protocol-mandated switching, overall survival is immature, and a safety profile including neutropenia, visual disturbances, and a potential cardiac signal with ribociclib is hard to justify in a clinically stable population. The vote is non-binding, but the message is that a strong progression-free survival signal triggered by a circulating tumor DNA biomarker alone is not enough to move stable patients to a new therapy.

🔹 Sun Pharma signed a definitive agreement to acquire Organon for $14 per share in cash, an enterprise value of $11.75B, the largest biopharma deal of 2026. Organon was spun out of Merck in 2021 with a portfolio of established brands and biosimilars. The combined company would have pro forma revenue of roughly $12.4B. This is about scale in established markets and a deeper biosimilars manufacturing base, and it signals that Indian generics and emerging market specialty pharma companies are now serious players in large cap consolidation in a way that Western companies have largely sat out. Section 232 tariff dynamics, which structurally disadvantage import-dependent biosimilar manufacturers, may have added strategic urgency to building US-domiciled scale.

🔹 Teva agreed to acquire Emalex Biosciences for $700M upfront plus up to $200M in milestones for ecopipam, a first in class dopamine D1 receptor antagonist that hit its Phase 3 primary endpoint in pediatric Tourette syndrome, with an NDA filing planned for the second half of 2026. Existing Tourette treatments carry significant tolerability burden in kids, largely through D2-mediated metabolic effects. A selective D1 mechanism that sidesteps that is genuinely differentiated, if the safety holds in broader use. The deal fits Teva’s ongoing effort to build a credible branded neuroscience franchise alongside its legacy generics business.

🔹 Eli Lilly reported Q1 revenue of $19.8B, up 56% year-over-year, with adjusted earnings per share of $8.55 versus consensus of $6.66. Mounjaro and Zepbound combined for $12.76B in the quarter, and Lilly raised full year revenue guidance to $82 to $85B. Foundayo, the oral GLP-1 launched April 1, wasn’t broken out separately, but launch data told a nuanced story: early IQVIA prescription tracking showed 3,707 scripts in week two, roughly five times fewer than oral Wegovy at the same stage, sending shares lower. Lilly pushed back on the earnings call, noting 20k patients were already on the drug and that around 8k prescribers had written Foundayo scripts, roughly a third of whom had never written an oral GLP-1 before. The broader earnings verdict is that GLP-1 pricing concerns haven’t materially dented the franchise. Volume growth is more than offsetting any pricing concession.

🔹 Boehringer Ingelheim reported Phase 3 results for survodutide, a once-weekly injectable glucagon/GLP-1 dual agonist licensed from Zealand Pharma, showing 16.6% weight loss versus 3.2% on placebo at 76 weeks in people with obesity or overweight without type 2 diabetes. The headline number is solid, though the topline release leaves tolerability questions open. Discontinuation rates hit 24.6% in Phase 2, and Phase 3 didn’t clearly address whether that improved. Full data will be presented at the American Diabetes Association meeting in June. No filing timeline has been announced, but Boehringer is positioning survodutide as a potential first dual GLP-1/glucagon agonist to reach the market.

🔹 The FDA launched a real time clinical trials initiative with AstraZeneca and Amgen as initial partners, targeting 20 to 40% reductions in trial timelines by receiving endpoint and safety data continuously rather than at completion. A request for information is open through May 29. Worth watching, but the operational burden of real-time reporting will favor larger sponsors with sophisticated data infrastructure over most mid-cap biotechs.

Share

WATCHLIST 👀

• Viridian Therapeutics REVEAL-2 (elegrobart, chronic thyroid eye disease): Phase 3 topline expected Q2 2026; possibly May

• Novo Nordisk Q1 2026 earnings - May 6: first commentary on competitive response to Foundayo and Mounjaro/Zepbound

• Vertex Q1 2026 earnings - May 4: Casgevy uptake and Alyftrek commentary

• Pfizer Q1 2026 earnings - May 5: Comirnaty and Paxlovid trajectory plus Vyndamax franchise commentary post-settlement

• Catalyst Pharmaceuticals (CPRX) Q1 earnings - May 11: possible Angelini bid commentary

• Merck IDVYNSO HIV launch - May 11: first week prescription read versus Biktarvy switch volumes

• Seaport Therapeutics IPO pricing: terms set at $16-$18 for $201M raise; pricing expected this week

• Hemab Therapeutics IPO pricing: terms set targeting $200M at $715M market cap

• ASCO 2026, May 29-June 2, Chicago: plenary session features Revolution daraxonrasib LBA5 (May 31) plus IDEAYA darovasertib LBA. Five plenary abstracts confirmed: PROTEUS, SARC041, LIBRETTO-432, HARMONi-6, and RASolute 302

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: iStock, avgust01

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

Merck’s Idvynso got FDA approval on April 21, a few days ahead of its scheduled review date, for virologically suppressed adults with HIV-1 looking to switch regimens. The significance isn’t the timing but what the drug represents, because for the first time, a suppressed patient can move to a two drug regimen that contains neither an integrase inhibitor nor tenofovir. Both drug classes are effective but carry long term baggage. Integrase inhibitors with weight gain and resistance accumulation risk, and tenofovir with renal and bone signals in susceptible patients. Idvynso won’t displace Biktarvy overnight, but it establishes a non-integrase standard of care in the switch setting that didn’t exist before.

Replimune had the opposite kind of week. The company received its second complete response letter for RP1 plus nivolumab in advanced melanoma, again on the same grounds: the trial couldn’t isolate what RP1 was actually contributing on top of a checkpoint inhibitor that already works well on its own. Replimune then announced layoffs of more than 200 people, roughly 60% of its workforce.

Kailera Therapeutics raised $625 million in its Nasdaq IPO, the largest biotech debut on record, for a Phase 2 obesity drug licensed from China’s Hengrui Pharma. That number says something about where investors sit right now. Lilly and Novo define the current GLP-1 battlefield, but the race for next gen differentiated mechanisms is still wide open, and the market is clearly willing to fund it at scale.

Beeline Medicines launched with $300 million in Series A funding built on five programs licensed from Bristol Myers Squibb, led by afimetoran, an oral TLR7/8 inhibitor in Phase 1b/2 for lupus with FDA Fast Track Designation. Same logic as J&J’s divestiture of bota-vec to MeiraGTx last week. These aren’t unwanted assets. Large companies are just concluding that focused independent teams run early precision immunology programs better than internal commercial machinery does.

AACR wrapped up April 22 in San Diego with Revolution Medicines presenting updated first-line daraxonrasib data alongside the already confirmed Phase 3 overall survival results. ASCO abstract titles dropped April 21, full data embargoed until May 29 through June 2 in Chicago, with the daraxonrasib Phase 3 RASolute 302 dataset confirmed for a plenary oral on May 31. The next six weeks will be the most data dense stretch of the year for precision oncology, and Revolution’s ASCO presentation is the one everyone is watching.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 The FDA approved Idvynso on April 21 for virologically suppressed adults with HIV-1 looking to switch off their current regimen. The once-daily single tablet pairs doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, which works through a distinct mechanism from conventional HIV drugs. Two Phase 3 trials supported the approval: a head-to-head against Gilead's Biktarvy showed identical efficacy at Week 48, and a switch trial showed 96% of Idvynso recipients maintained viral suppression. The clinical argument is straightforward: long-term exposure to the drug class in Biktarvy carries associations with weight gain and metabolic effects, and tenofovir carries renal and bone signals in some patients. Idvynso removes both in a single pill. Commercial availability begins May 11, and the switch population is large. The real launch question is formulary access.

🔹 Replimune received a second complete response letter for RP1 in combination with nivolumab for advanced melanoma, and the FDA's concern hasn't changed: a single-arm trial can't isolate what the drug is actually contributing on top of nivolumab alone. The company followed the news with layoffs of more than 200 employees, roughly 60% of its workforce. The broader lesson for the oncolytic virus field is hard to ignore: compelling early signal in open-label studies does not survive FDA scrutiny if the registration design can't answer the additive benefit question. Any future combination program will need a randomized arm comparing the backbone therapy alone. That's the bar now.

🔹 Kailera Therapeutics raised $625M in its Nasdaq IPO, the largest biotech debut on record, surpassing Moderna's 2018 raise. The company's lead program is oral ribupatide, a GLP-1/GIP dual agonist currently in Phase 2 for obesity, licensed from China's Hengrui Pharma. That China angle matters: Hengrui has one of the more productive GLP-1 pipelines outside the US, and Kailera is essentially a vehicle to bring that chemistry into the American development and regulatory system. The size of the raise signals that investors aren't waiting for the Lilly versus Novo battle to resolve before backing the next wave of obesity drugs.

🔹 Beeline Medicines launched April 15 with $300M in Series A financing, built around five programs licensed from Bristol Myers Squibb targeting immune-mediated diseases. The lead asset is afimetoran, an oral TLR7/8 inhibitor in Phase 1b/2 for lupus with FDA Fast Track Designation, with a Phase 2 readout expected in the second half of 2026. The pipeline also includes a TYK2 inhibitor and an IL-2/CD25 fusion protein. The structure mirrors what we've seen elsewhere recently: a large pharma deciding a set of early-stage programs is better run in a leaner, focused vehicle than inside a commercial organization. BMS keeps some economics, Beeline gets the operational flexibility. Whether afimetoran can compete in lupus against established options like belimumab and anifrolumab depends on tolerability, and the Phase 2 data will be the first real read on that.

🔹 The FDA approved Sanofi/Regeneron’s Dupixent (dupilumab) for chronic spontaneous urticaria, a condition causing persistent unpredictable hives, in children aged 2 to 11 who don't respond adequately to antihistamines. This is Dupixent's ninth allergy-related indication. The approval was supported by Phase 3 data from the LIBERTY-CUPID program in adolescents and adults plus pharmacokinetic and safety data in the target pediatric age group. No single pediatric label expansion moves the needle much on a drug already doing over $16B a year, but Sanofi and Regeneron have been methodical about this: build formulary positioning across the entire atopic disease spectrum, one indication at a time.

Share

CLINICAL TRIAL UPDATES 📊

🔹 Doravirine / Islatravir (Merck) - Phase 3, HIV-1. The two trials behind the Idvynso approval are covered above. The clinical read is clean and the non-inferiority bar against Biktarvy is met. The standard for any competitive HIV switch study is now a head to head against an approved non-integrase inhibitor regimen at Week 48, and Merck cleared it.

🔹 Daraxonrasib (Revolution Medicines) - Phase 1/2, first-line metastatic pancreatic cancer. Revolution presented early first-line data at AACR this week, though full efficacy numbers remain embargoed until the slides are released. What’s notable is that Revolution has submitted for a plenary presentation at ASCO for the Phase 3 dataset, which signals internal confidence in the full data package. The scientific question worth watching is whether the drug’s multi-variant RAS targeting works as well in first-line patients, whose tumors haven’t yet been shaped by chemotherapy selection pressure, as it does in the second-line setting where the landmark results came from. Still early, still small cohorts, but the first-line ambition is clearly alive.

WATCHLIST 👀

• ASCO 2026 abstracts: Full abstracts release May 21; meeting runs May 29 to June 2 in Chicago

• Daraxonrasib (Revolution Medicines): Phase 3 RASolute 302 plenary presentation, Abstract LBA5, May 31, ASCO 2026

• Darovasertib + crizotinib (IDEAYA): Phase 2/3 OptimUM-02 late-breaking oral presentation, ASCO 2026; NDA submission targeted H2 2026

• Viridian elegrobart: REVEAL-2 readout (chronic thyroid eye disease) expected Q2 2026; BLA targeted Q1 2027

• Lilly Foundayo T2D NDA: Filing targeted end of Q2 2026; ACHIEVE-4 MACE HR 0.84 and all-cause mortality HR 0.43 (not multiplicity-controlled) are the supporting data

• Beeline afimetoran (SLE): Phase 2 completion targeted H2 2026; pivotal decision to follow

• Novartis pelacarsen (Lp(a)HORIZON): Lp(a) lowering cardiovascular outcomes trial; timing on readout not confirmed but widely described as a high-stakes event for 2026; watch for announcement

• IDVYNSO commercial launch: Available in pharmacies after May 11; payer formulary positioning and switch uptake versus Biktarvy will be early launch metrics to watch

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: iStock, avgust01

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

April 13 may turn out to be one of the more important single days in pancreatic cancer research in a generation. Revolution Medicines posted a landmark Phase 3 result in second-line metastatic pancreatic cancer, a disease where chemotherapy produces median overall survival of roughly six to seven months, and where nothing has meaningfully moved that number in over a decade. The trial posted 13.2 months, with a hazard ratio of 0.40, meaning a 60% reduction in the risk of death versus chemotherapy, delivered as a once daily oral pill. If this holds through full data review, daraxonrasib becomes the standard of care for RAS-mutant second-line pancreatic cancer, which is essentially all of it, and Revolution becomes a serious acquisition target.

On the same morning, IDEAYA Biosciences reported a clean Phase 3 readout in uveal melanoma, a rare eye cancer with no approved first-line treatment for the relevant patient subgroup. The overall response rate was 37.1% versus 5.8% for investigator’s choice, with a hazard ratio of 0.42 on progression-free survival. Smaller population than pancreatic cancer, but an equally unambiguous result. An NDA filing is targeted for the second half of 2026. Two clean results in two notoriously hard indications on the same morning is not something that happens often.

The Foundayo story moved forward on two fronts. The FDA asked Lilly for post-marketing studies covering liver injury, thyroid cancer risk, and long-term cardiovascular outcomes, which is standard for a new mechanism being deployed at massive scale, not a red flag. Lilly responded with ACHIEVE-4, their largest and longest orforglipron trial to date: 2,749 patients with type 2 diabetes and elevated cardiovascular risk, non-inferior cardiovascular outcomes versus insulin glargine, no liver signal, 8.1 kg of weight loss versus a 1.4 kg gain on the comparator, and all-cause mortality 57% lower with Foundayo, though that last number wasn’t controlled for multiple comparisons and should be read carefully. The T2D filing is on track for Q2.

On the policy side, the FDA scheduled an advisory committee review to reconsider restrictions on several compounded peptides that were flagged for safety concerns back in 2023. The practical read is that compounding boundaries directly affect demand for branded alternatives, safety narratives around entire drug classes, and how aggressively telehealth platforms can operate. When those boundaries get revisited, it creates real uncertainty for companies that have been planning around the existing framework. On the capital side, the market is open but selective. Revolution pulled in a $2B financing on the back of its Phase 3 data in a single move, while smaller players like MeiraGTx had to get creative with asset reacquisitions and targeted equity raises. Lilly also added to its oncology portfolio, acquiring CrossBridge Bio for up to $300M to get its hands on a dual-payload TROP2 antibody drug conjugate at the pre-IND stage. Small deal, but consistent with a deliberate pattern of building out targeted delivery capabilities before the competitive window closes.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 In an unusual reversal of the typical deal direction, MeiraGTx announced on April 16 that it is acquiring botaretigene sparoparvovec (bota-vec) back from J&J for $25M upfront, with a single milestone payment due on U.S. approval and royalties to J&J starting in mid-2029. Bota-vec is an AAV-based gene therapy targeting RPGR-associated X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease causing progressive vision loss in an estimated 20k patients in the U.S. and EU with no approved treatment. The FDA has granted Fast Track and Orphan Drug Designations; the EU has granted PRIME and ATMP designations. MeiraGTx targets regulatory filings in the U.S. and EU in 2027. For MeiraGTx, this clears the path to commercialize a program it originated.

🔹 The FDA scheduled advisory committee review to reconsider restrictions on several compounded peptides that had been placed in a category associated with significant safety concerns in 2023. The agency is moving to reclassify multiple substances, with meetings planned in 2026 and early 2027. This is a policy volatility signal for biopharma and telehealth alike, because compounding boundaries influence demand flows, safety narratives, and future enforcement assumptions.

🔹 Lilly announced on April 14 the acquisition of CrossBridge Bio, a Houston-based startup spun out of UTHealth Houston, for up to $300M in cash (upfront plus a development milestone). CrossBridge’s lead asset is CBB-120, a TROP2-targeting antibody-drug conjugate (ADC) that delivers two payloads simultaneously: a topoisomerase 1 inhibitor and an ATR kinase inhibitor. The crowded TROP2 ADC space already has two approved single-payload drugs in Trodelvy and Datroway, and the bet with CBB-120 is that hitting two biological targets simultaneously generates more durable responses and makes it harder for tumors to develop resistance. IND filing for CBB-120 is targeted for 2026. This is Lilly’s latest oncology platform add, following its ongoing expansion into degraders and conjugate hybrids. Section 232 tariff exemptions for ADCs further advantage this category. The deal is expected to close in Q2 2026.

🔹 Roche said it will launch a new global Phase 3 trial for Elevidys in early ambulatory Duchenne muscular dystrophy patients, randomizing about 100 participants to Elevidys or placebo over 72 weeks with time-to-rise as the primary endpoint. The study is designed to support a resubmission in Europe after the prior negative opinion from the EMA. This resets expectations for a longer and more data-intensive European path and reinforces that gene therapy commercialization is now a multi-cycle evidence process.

🔹 Replimune began layoffs after receiving a second complete response letter on RP1 in advanced melanoma, including a reported reduction of 63 employees this month, while management continues to argue the therapy’s activity profile remains clinically meaningful. This is the execution penalty in real time when accelerated approval strategy fails to align with regulator expectations.

Share

CLINICAL TRIAL UPDATES 📊

🔹 Daraxonrasib (Revolution Medicines) - Phase 3 [RASolute 302], 2L metastatic pancreatic ductal adenocarcinoma (PDAC). In what may be the most important oncology data package of 2026 so far, Revolution Medicines announced on April 13 that its RAS(ON) multi-selective inhibitor daraxonrasib met both primary endpoints in the RASolute 302 Phase 3 trial: statistically significant improvement in both progression-free survival and overall survival (OS) versus investigator’s choice chemotherapy in approximately 460 previously treated metastatic PDAC patients. Median OS was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy. That is nearly double the survival achieved by gemcitabine/nab-paclitaxel or FOLFOX in the second-line setting. The drug targets RAS(ON) mutations, which drive tumor growth in approximately 90% of pancreatic cancer cases, making this a broadly applicable result. Safety was manageable with no new signals. Revolution plans to submit an NDA using an expedited national priority review pathway enabling a one-to-two month review timeline. A first-line PDAC Phase 3 (RASolute 303) is already enrolling. Shares surged on the news.

🔹 Darovasertib + crizotinib (IDEAYA Biosciences / Servier) - Phase 2/3 [OptimUM-02], 1L HLA-A*02:01-negative metastatic uveal melanoma. The regimen met its primary endpoint in 313 patients with median progression-free survival 6.9 months versus 3.1 months. Objective response rate was 37.1% versus 5.8%, including five complete responses in the combination arm. This remains one of the cleanest efficacy signals this week in a hard to treat setting, with overall survival maturity still the key open variable.

🔹 Orforglipron / Foundayo (Eli Lilly) - Phase 3 [ACHIEVE-4], type 2 diabetes with obesity and elevated cardiovascular risk. Lilly dropped the largest and longest Foundayo (orforglipron) trial to date, ACHIEVE-4, covering 2,749 patients with type 2 diabetes and elevated cardiovascular risk across 15 countries. Against insulin glargine, Foundayo met cardiovascular non-inferiority, cut weight by 8.1 kg versus a 1.4 kg gain on the comparator, and reduced A1C by 1.6% versus 1.0%. The headline number that will get attention: all-cause mortality was 57% lower with Foundayo, though that result wasn’t controlled for multiple comparisons so it needs to be interpreted carefully. Lilly plans to file for a type 2 diabetes indication by end of Q2 2026.

WATCHLIST 👀

• Merck DOR/ISL (doravirine/islatravir) - PDUFA April 28; if approved, first once-daily two-drug HIV regimen without an integrase inhibitor; watch for any impact on Gilead’s Biktarvy franchise

• Viridian Therapeutics / elegrobart - REVEAL-2 (chronic thyroid eye disease) topline data expected Q2 2026; REVEAL-1 (active TED) was positive; BLA filing targeted Q1 2027

• IDEAYA / darovasertib+crizotinib - NDA filing H2 2026; first potential approval in first-line uveal melanoma

• Revolution Medicines / daraxonrasib - NDA submission timing TBD; ASCO 2026 data presentation upcoming; RASolute 303 (1L PDAC) now enrolling

• Eli Lilly / Foundayo (T2D) - NDA submission by end of Q2 2026; FDA will evaluate against ACHIEVE-4 data and post-marketing study framework from obesity approval

• Section 232 tariffs - July 31, 2026 effective date for Annex III companies; ADC/cell gene/orphan/plasma-derived biologics remain exempt; watch for pre-July deal acceleration in tariff-exposed modalities

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

Gilead committed another $3.15 billion upfront to acquire Tubulis, an antibody-drug conjugate company, bringing its total dealmaking this year to roughly $11 billion across three transactions. Meanwhile, the backstory on Merck’s Terns acquisition finally came out via SEC filings. Merck originally offered $61 per share, updated trial data on TERN-701 showed a lower response rate than previously disclosed, the competing bidder walked away, and the deal settled at $53 after Terns negotiated up from Merck’s revised $50 offer. The final price still looks cheap to most analysts, but the process showed that even highly anticipated assets get repriced when data gets more nuanced in due diligence.

Lilly launched Foundayo with self-pay pricing starting at $149 per month, and the commercial argument centers on convenience - no food or water timing restrictions, fast fulfillment, and an accessible entry price. The competition between Lilly and Novo Nordisk has shifted from clinical trial comparisons to adherence, payer contracts, and logistics, and that dynamic will play out over years.

On the science side, Roche and C4 Therapeutics expanded their collaboration into degrader antibody conjugates, combining targeted delivery with payload biology that destroys disease-causing proteins rather than just blocking them. Still preclinical, but the investment in the concept is notable. Clinical results elsewhere were mixed. Sanofi’s lunsekimig won in airway disease but missed in atopic dermatitis, and Insmed dropped another indication for Brinsupri after a mid-stage failure. Capital is going to programs with tight translational logic and away from broad indication expansion without it.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 Gilead agreed to acquire Tubulis for $3.15B upfront plus up to $1.85B in milestones, adding clinical stage and preclinical antibody drug conjugate programs and expanding Gilead’s internal payload and linker capabilities. The transaction values Tubulis at up to $5B and is expected to close in Q2. This is another signal that large cap oncology buyers are paying for technical depth in chemistry and design, not just target novelty. Gilead has now committed about $11B across three deals this year, which makes the company’s diversification push harder to dismiss as incremental portfolio maintenance.

🔹 The CDC’s acting director Jay Bhattacharya has delayed publication of a CDC report showing that updated COVID vaccines cut the risk of emergency department visits by about 50% and hospitalizations by roughly 55% in healthy adults last winter. The study, based on data from September through December and originally scheduled for publication on March 19 in the CDC’s Morbidity and Mortality Weekly Report, used a methodology called test-negative design, a well-established approach the agency has relied on for years to evaluate respiratory virus vaccines. Bhattacharya has raised concerns about that methodology, and HHS framed the delay as routine leadership review. Former CDC official Dan Jernigan pushed back, arguing the findings simply don’t align with the direction RFK Jr. has taken on vaccines, noting that suppressing evidence of vaccine effectiveness while simultaneously rolling back COVID shot recommendations for children and pregnant women sends a deeply contradictory public health message.

🔹 Merck’s $6.7B acquisition of Terns Pharmaceuticals got more interesting this week when SEC filings revealed the real negotiation behind the headline number. Four companies were originally bidding, and Merck’s initial offer was $61 per share, about $1B more than the final price. What changed: updated data from the CARDINAL trial showed that TERN-701’s major molecular response rate at 24 weeks came in lower than the 64% figure Terns had presented at a December conference. Merck cut its offer to $50, the competing bidder walked away entirely, and Terns negotiated back up to $53. William Blair, which had previously floated the possibility of a counterbid, now says a competing offer is unlikely and expects the deal to close in early May.

🔹 Lilly formally launched Foundayo (orforglipron) in the U.S. after FDA approval last week, opening prescriptions immediately with shipping starting April 6. Lilly highlighted ATTAIN 1 data showing average weight loss of 12.4% among trial completers at the highest dose, and self pay pricing that starts at $149 per month on the lowest dose. The oral GLP-1 race is now live, not theoretical. Novo Nordisk had a three month head start in oral obesity, and Lilly responded with a convenience argument that Foundayo can be taken without food or water restrictions. This does not automatically dethrone Novo, but it changes the commercial battlefield from pure efficacy comparison to adherence friction, fulfillment speed, and net pricing strategy.

🔹 Roche and C4 Therapeutics expanded their long running targeted protein degradation relationship with a new degrader antibody conjugate collaboration. C4T receives $20M upfront, potential milestone payments exceeding $1B across discovery, regulatory, and commercial events, and tiered royalties if products launch. This is a concrete sign that oncology modality convergence is accelerating. Antibody drug conjugates already validated targeted delivery, and degraders promise catalytic biology beyond occupancy inhibition. The combination can expand target space if safety and therapeutic index hold up in humans. It is still early, still unproven clinically, but strategically this is where next cycle optionality is being built.

Share

CLINICAL TRIAL UPDATES 📊

🔹 Lunsekimig (Sanofi) - Phase 2 across asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Sanofi reported a split outcome: positive reads in asthma and chronic rhinosinusitis with nasal polyps, but failure in atopic dermatitis. Public coverage has not yet provided full endpoint level tables and denominator level detail across all cohorts, so the current read remains directional rather than complete. One clean signal in airway disease does not grant automatic credibility in dermatology. The next key step is whether Sanofi narrows to the strongest biology defined populations or continues broad indication expansion with a higher execution burden.

🔹 Subcutaneous Tepezza (Amgen) - Phase 3 in thyroid eye disease. Amgen said a subcutaneous formulation of Tepezza was comparable to the infused version in a pivotal setting. Full numerical disclosure remains limited in open access summaries, but the route of administration signal is clear. Convenience is now part of competitive defense in thyroid eye disease as oral and subcutaneous challengers, including Viridian Therapeutics, move closer to market. Improved administration logistics can protect incumbent share even before head to head superiority data exist.

🔹 Brinsupri (Insmed) - mid stage hidradenitis suppurativa program discontinued. Insmed stopped Brinsupri in hidradenitis suppurativa after a mid stage miss, adding to a prior discontinuation in sinus inflammation. Serial indication failures force portfolio triage and tighter capital allocation. In this market, investors are not rewarding broad anti inflammatory expansion without strong translational logic and a visible efficacy gradient early in development. Next for Insmed is focus and redeployment into assets with cleaner probability weighted paths.

WATCHLIST 👀

• Oral obesity net pricing: whether Lilly and Novo keep matching low entry prices or shift to tighter dose tier economics as payer negotiations deepen.

• Gilead post close integration: timeline updates for Tubulis programs and whether management changes development sequencing this quarter.

• Merck TERN-701 clinical disclosures: deeper molecular response and safety detail ahead of broader investor scrutiny on best in class claims.

• DAC modality validation: first meaningful preclinical to clinical translation markers from Roche and C4T’s degrader antibody conjugate strategy.

• Immunology indication narrowing: Sanofi’s development path decision after lunsekimig’s mixed read across three diseases.

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: Hannah Beier (Reuters)

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.

👥 If you haven’t already, please connect with me or follow me on LinkedIn.

VIDEO SUMMARY

THIS WEEK’S KEY TAKEAWAYS 🔑

Eli Lilly paired a fast regulatory win for Foundayo (orforglipron) with a large strategic acquisition of Centessa, while Biogen bought Apellis for near term commercial cash flow and nephrology field infrastructure. Those moves all point to thee fact that large buyers are still willing to pay real money, but mostly when uncertainty is constrained and launch math is visible.

Yesterday, the White House moved to impose 100% tariffs on a subset of branded pharmaceutical imports from countries without qualifying trade arrangements, with carveouts and phased implementation language shaping the near term impact. The immediate business effect is not simple demand destruction. It is supply chain repricing risk, gross margin uncertainty, and fresh pressure to localize active pharmaceutical ingredient and finished dose manufacturing for politically exposed products. Even before full implementation details settle, boards now have to model trade policy as a core variable.

The obesity narrative also got more strategic in the last 48 hours. Lilly now has the first approved oral small molecule GLP-1 option for chronic weight management that can be taken without food or water timing constraints. Novo Nordisk quickly challenged comparative claims in public, which is exactly what a mature two player market looks like when convenience and efficacy are both investable endpoints. This no longer reads like a single winner category. It reads like a multiyear channel battle across adherence, payer access, and real world persistence.

Clinical data reinforced a stricter quality bar. Immunovant reported that batoclimab failed both pivotal thyroid eye disease studies on the primary endpoint, while Beam continued to publish early but encouraging base editing data in sickle cell disease. The market is being pretty blunt. Late stage misses get punished immediately, and early platform wins only matter if they keep turning into durable efficacy with strong execution.

Subscribe now

BIOTECH/PHARMA NEWS 🧬

🔹 U.S. administration signed an order setting 100% tariffs on certain imported branded drugs and active pharmaceutical ingredients from countries without qualifying trade deals, with carveouts that appear designed to limit immediate disruption while preserving political leverage. For operating teams, the implication is not just customs cost pass through. It is contract manufacturing renegotiation, product specific sourcing triage, and potential gross to net pressure if pricing actions face payer resistance. Investors now need to underwrite policy implementation risk product by product, not simply at sector level.

🔹 Eli Lilly consolidated an unusually strong week by combining regulatory speed and strategic M&A. The FDA approved Foundayo (orforglipron) for chronic weight management in adults with obesity, or overweight with at least one weight related comorbidity, and did so 50 days after filing under the Commissioner’s National Priority Voucher program. Lilly then announced the acquisition of Centessa for $38/share in cash, valuing the transaction at about $6.3B upfront, plus a contingent value right worth up to $9 per share linked to orexin receptor 2 program milestones. The strategic logic is that obesity generated scale is being recycled into adjacent, high value chronic disease franchises where first movers can still build durable share.

🔹 Merck signed a collaboration that could reach $838M in milestones for antibody candidates generated against multiple undisclosed targets, with economics weighted to downstream achievements. The headline matters less than the structure. Large pharma still wants external biologics throughput, but prefers options and staged risk transfer over heavy upfront checks for preclinical stories. That framework raises the execution burden for platform companies: it is no longer enough to show technical novelty, you need repeatable asset quality and partner relevant timelines.

🔹 Biogen agreed to acquire Apellis for $41 per share in cash, approximately $5.6B upfront, with additional contingent value rights tied to Syfovre sales milestones. The deal adds two marketed complement pathway products and an established nephrology commercial footprint while Biogen advances internal kidney programs. Apellis reported $690M in 2025 net product revenues across Syfovre and Empaveli, which gives Biogen immediate top line contribution rather than a long precommercial wait. In this funding tape, that is exactly the type of asset profile that clears internal return hurdles for large buyers.

🔹 IO Biotech moved toward bankruptcy after failing to secure a buyer or financing path following pivotal disappointment in its cancer vaccine program. The company disclosed intent to seek bankruptcy protection, underscoring how quickly a late stage miss plus weak capital access can collapse strategic optionality. This is the opposite side of the same market that rewarded large cap buyers this week. Capital exists, but it is selective and often binary around data credibility and near term commercial visibility.

Share

CLINICAL TRIAL UPDATES 📊

🔹 Batoclimab (Immunovant) - Phase 3, thyroid eye disease: Immunovant reported that both pivotal studies, TIDE-1 and TIDE-2, missed the primary endpoint of at least a 2 millimeter reduction in proptosis at Week 24 versus placebo. The company also said one secondary endpoint, diplopia responder rate, was not statistically significant in either study, while another secondary endpoint, Clinical Activity Score of 0 or 1, reached statistical significance in one trial but not the other. Safety was described as generally consistent with prior batoclimab experience, with no newly identified signal that altered overall interpretation. This was not a clean enough efficacy package to support a credible TED path for batoclimab, and management signaled focus would remain on next generation FcRn assets.

🔹 BEAM-101 (risto-cel) (Beam Therapeutics) - Phase 1/2, sickle cell disease: Beam announced publication of BEACON data in The New England Journal of Medicine, reinforcing the early thesis that base editing can durably raise fetal hemoglobin and reduce vaso occlusive events in treated patients. Patient counts remain limited and follow up is still maturing, so this is not yet a registrational level dataset. But the translational signal continues to hold up across company updates and peer reviewed presentation, which keeps the platform competitive in the broader one time treatment race for hemoglobinopathies. The practical next step is scaling enrollment and durability follow up while demonstrating manufacturing consistency at higher throughput.

WATCHLIST 👀

• U.S. pharma tariff implementation details: country scope, product exemptions, and active pharmaceutical ingredient treatment will drive near term margin modeling and supply chain changes.

• Orca Bio, Orca-T: FDA extended review to July 6 after additional chemistry, manufacturing, and controls submission.

• Viridian Therapeutics, REVEAL-2: chronic thyroid eye disease Phase 3 readout expected in Q2, key for commercial positioning after REVEAL-1 debate.

• Lilly vs Novo oral obesity positioning: comparative messaging fight will likely shift quickly toward payer contracts and persistence data.

• Biogen integration of Apellis assets: early commercial execution and nephrology channel retention will signal whether the deal thesis converts into growth.

Subscribe now

Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.

Cover image credit: Andrew Leyden/NurPhoto via AP